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ABSTRACT

Alzheimer’s Disease (AD) is a neurodegenerative disorder that affects around 50 million people
worldwide and causes cognitive decline, brain atrophy and death. Despite extensive basic and clinical studies and drug development efforts, currently no effective treatments are available for AD.
The amyloid β (Aβ) peptide is neurotoxic and is tightly associated with AD pathology, but the
molecular mechanism of its action remains unclear. There are various forms of Aβ in the brain,
ranging from the full length Aβ1−42 to shorter peptides, such as a strongly toxic Aβ25−35 fragment.
The Amyloid Cascade Hypothesis (ACH) postulated that extracellular Aβ deposits cause the disease. More recently, the soluble Aβ oligomers came into the focus of research as they proved to be
the major neurotoxic entities. One of the mechanisms by which Aβ peptides, including Aβ25−35 ,
kill neurons is membrane perforation and disruption of cellular homeostasis. Although direct membrane interaction and pore formation by Aβ has been documented, the detailed structural aspects
of membrane pores remain elusive. Here, we quantitatively describe the structure of Aβ25−35 in
aqueous buffer and in lipid environment, its binding to membranes, pore formation, and the details
of membrane pores. We have shown that membrane binding of Aβ25−35 is electrostatically driven.
Aβ25−35 forms β−barrel like structures ranging from hexamers to octamers and then assemble
into supra−molecular structures forming calcium−conducting pores in the membrane with radius
of 6 Å to 7 Å. The structural features of Aβ25−35 pores depend on the content of cholesterol in the
membranes. Moreover, the aggregation and structural changes of a series of Aβ fragments have
been analyzed to identify the segment(s) of highest propensity for fibrillogenesis that might serve
as initiators of Aβ aggregation and conversion into toxic species. Finally, the structures of the
full−length Aβ1−42 and a hypertoxic version pEAβ3−42 , in lipid environment have been analyzed
by solid state nuclear magnetic resonance. Collectively, these studies will elucidate the structural
details of membrane pores formed by Aβ peptides as targets for new anti−AD therapies.
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CHAPTER 1: INTRODUCTION

Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by gradual decline in cognitive abilities including memory loss. Despite of extensive research and investment, the central
role of amyloid beta (Aβ) in Alzheimer’s Disease and the molecular mechanism of its toxicity are
still controversial. Many clinical trials of AD drug candidates targeting classical neuropathological features of AD have not been successful so far. Most of the experimental works have not been
conclusive and in silico works have resulted in very divergent models of the Aβ peptide and its
role in AD pathology. These classical lesions also appeared in brains without AD. Moreover, it
was also found that about one third of cognitively normal older persons built amyloid plaques in
cerebral region. This fact seriously questioned the paradigm of amyloid cascade hypothesis. This
has caused a shift in the hypothesis from all Aβ burden to small soluble toxic oligomers. These
intermediates bind to the membrane, assemble into a fixed structure and result in membrane damage, pore/channel formation and calcium dysregulation in neuronal cells. This research is focused
to provide molecular details into the formation of pore/channel by Aβ peptide in phospholipid
membranes.
This dissertation work focuses on molecular basis of membranotropic effect of Aβ peptides using various techniques: fluorescence spectroscopy (FS), Fourier transform infrared spectroscopy
(FTIR), circular dichroism (CD), Forster resonance energy transfer (FRET) and solid state nuclear magnetic resonance (ssNMR). The first part is based on characterization of membrane pores
formed by an undecapeptide Aβ25−35 with sequence (GSNKGAIIGLM) with a detailed analysis
of these structures. The second part presents the analysis of the structure of Aβ25−35 in lipid membrane and the role of cholesterol in pore formation activities of the peptide in the lipid membrane.
It also covers some FRET experiments for the detection of aggregation in early stages i.e. formation of peptide oligomers that precede fibril formation. The third and final part of this dissertation
1

summarizes on the conformational changes occurring in peptides Aβ1−42 and pEAβ3−42 in the
presence of lipid membrane.
In the first part, a detailed analysis of Aβ25−35 binding to lipid membranes and resulting pore formation under different salt concentration has been discussed. CD and FTIR were used to analyze
the structural changes of peptide in aqueous buffer. Membrane binding mechanism was analyzed
using microelectrophoresis data in terms of ζ−potential and binding constants. Binding site densities were also calculated using these data. Detailed mode of binding affinity, kinetics of different
species of peptides formed during incubation in buffer and in membrane have been presented.
Similarly, the membrane permeabilization assay was performed using Quin−2 fluorescence under
various conditions of salts and membrane charge. The structure of these pore forming species was
monitored using CD under various experimental conditions to find structure and molecular state of
these membrane disturbing assemblies.
Second part describes the biophysical techniques used to characterize structure of the pore. The
peptide structure in lipid membrane and the effect of varying concentration of cholesterol on the
structure and function of the pore was identified. The quantitative analysis of peptide assemblies,
structure and oligomeric state of the pore have been presented. The molecular events occurring
in the membrane with different cholesterol were analyzed. The order and homogeneity of lipid
membrane with peptide incorporated, the orientation of peptide, the mode of calcium transport
with different possible structures of pore−assembly have been demonstrated.
The third section covers on FRET experiments designed to capture the oligomeric species of
Aβ1−42 before formation of fibrils. Based on the position of phenylalanine (Phe) and tyrosine
(Tyr) and also depending on change and hydrophobicity of residues, different truncation variants
of Aβ1−42 were used. The aggregation studies are usually carried out using exogenous fluorophores
which are insensitive to early stages of aggregations and might themselves affect fiber formation.
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In order to identify segment that initiates aggregation and connect the total pathway of aggregation
starting from very early stages to final matured form, we combine FRET between Phe and Tyr,
ThT−fluorescence, FTIR and CD measurements.
The final section of this work summarizes the structure−function relationship of Aβ1−42 and
pEAβ3−42 in lipid membrane and associated toxicities. As the amyloid plaque consists of all
species of Aβ peptide including the most dominant Aβ1−40 and more toxic Aβ1−42 and pEAβ3−42 ,
the purpose here is to extrapolate the results of the membranotropic effect of shorter variant
Aβ25−35 to these full length counterparts. The work is aimed at characterizing the detail tertiary
structure of the membrane bound structure and associated pore/channel formation by peptides
Aβ1−42 and pEAβ3−42 in lipid membrane using FTIR and ssNMR. If we can understand the entire mechanism of these different truncation variants along with full length peptides, this would
contribute to therapeutic measures for the control of this devastating disease.
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CHAPTER 2: LITERATURE REVIEW

2.1

Alzheimer’s Disease: Progress and Challenges

Alzheimer’s disease (AD) is the main cause of dementia which is characterized by two main
lesions; positive lesions of extracellular regions of senile plaques consisting of cross β−sheet
conformation of Aβ peptide [1, 2, 3], cerebral amyloid angiopathy, intracellular deposits of neurofibrillary tangles consisting of phosphorylated tau protein and glaial responses accompanied by
neuronal and synaptic losses [4, 5, 6, 7, 8, 9, 10]. AD affects millions of people worldwide and
is currently incurable. After the discovery of these plaques in the brains of Alzheimer’s patients,
it was believed that Aβ burden was the main cause of this disease [4, 11, 12]. This postulate was
also referred to as amyloid cascade hypothesis (ACH). This theory assumed that the neurons are
badly damaged by the plaques several years before unset of dementia. Amyloid imaging tracers
were also developed to track the progression of AD and the role of anti−amyloid therapy in these
events [13]. Structure based inhibitors of pathological amyloid fibrils have also been studied to
disrupt the fibril formation [14]. It was also shown that increasing the levels of longer amyloid
beta over shorter fragments put the individual at higher risk of developing AD without altering the
progression time of the disease [15]. However, even after several years of intense research based
on this hypothesis, there were no clear indications to support this argument. Instead, people found
some buffering role of those plaques [16].
It is reported that abnormal Aβ processing and resulting deposits of Aβ is essential but not sufficient for developing Alzheimer’s disease [17]. Protein assembly begins in specific regions of the
brain and then spreads out to other regions. Another conflicting observation was that about one
third of the people who have very normal cognitive abilities developed plaques in cerebral regions
[18]. Many clinical trials targeting these classical neuro−pathological features of AD have not
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been successful so far [10, 12]. These classical lesions also appeared in brains without AD and
sometimes ten to fifteen years before the symptoms of AD. This fact seriously questioned the AD
paradigm and put the key role of Aβ on these molecular events in doubt. It is still not clear whether
the amyloid fibrils are the cause of AD pathology or if alternatively, they have a protective function, while the pathological cause is the amyloid membrane disruption activity. Hence the whole
mechanism of toxicity still remains controversial. If we can establish a clear experimental evidence
elucidating the structure−function relationship of amyloid beta, then the design of molecules able
to interact with the amyloid peptides as inhibitors of fibril formation or as inhibitors of amyloid
membrane pore formation will constitute a basic approach in the development of anti−Alzheimer
therapies [19, 20].
It has now been suggested that well before formation of plaques, smaller forms of oligomers appeared to be toxic to neurons disturbing their communication [9, 21, 22, 23, 24]. However, despite
the numerous works supporting the central role of Aβ oligomers in AD, the exact molecular events
of oligomer formation and underlying toxicity are still unclear [25]. Although the formation of
ion−channels or amyloid pores have been put forward as AD pathology, the molecular mechanism
of pore/channel formation is still lacking. Some studies have suggested the structure of pore as
a β−barrel [26, 27] while others have suggested the formation of oligomeric ion channels by self
assembly with tilted α−helical topology [28]. This inconsistency shows that the structure of pore
is not known yet. It demands more clarification to resolve this inconsistency by determining the
pore structure experimentally with the peptide in a lipid environment rather than in silico or in
aqueous buffer.
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2.2

Membrane Interactions of Different Aβ Variants

Aβ peptide is produced from the amyloid β precursor protein (APP) found in neuronal membrane
by proteolytic activity of β and γ secretases [29, 30]. Poor sequential specificity of γ secretase results in different Aβ species such as Aβ1−42 , Aβ1−40 , Aβ25−35 , Aβ17−42 and so on with Aβ1−40 and
Aβ1−42 being the dominant species. The peptide Aβ1−42 has been reported to be less abundant but
more toxic than Aβ1−40 or any other fragments [22]. The APP post processing pathway is still unclear. Aβ can form a varieties of β−sheet rich aggregates. It has been reported that Aβ oligomers
undergo a conformational transition to highly toxic beta sheet structures from initial α−helical or
some random coil structure [31]. Neurotoxicity is believed to be related to different membrane
interactions and destabilization processes of those oligomers through membrane permeation and
pore formation. Membrane pore formation studies have been done mostly in silico and the results
are very divergent based on choice of initial peptide structure. The structure reported range from
different β−barrel [26, 27] to various α−helical pores [32, 33, 34, 35, 36, 37]. Tsai et al. [32, 33]
and Dies et al. [38] used detergent−solubilized partially α−helical structure [39, 40]. Fantini and
co−workers [34, 35, 36, 37] used α−helical 25 to 35 stretch of Aβ1−40 in micelles [41] while
Chang et al. [26] used preformed octameric β−barrel structure.
Other Aβ derivatives including full length peptide have also been reported to form similar pore
structure i.e. β−barrel models consisting of 12 to 18 subunits for Aβ1−42 , Aβ9−42 , and Aβ17−42
[42, 43]. Tetramers and/or pentamers of 16−stranded β−barrels have been reported for Aβ9−42
and Aβ17−42 with 64 to 80 peptide monomers in the pore [44]. Similarly, hexamers of 6−stranded
β−barrels were also reported for Aβ1−42 consisting of 36 monomers [45]. Moreover, Aβ arctic
mutant forming pore−like structures with 40 to 60 molecules [46] have also been reported.
The full length Aβ with sequence DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA is an amphiphilic peptide. Aβ1−42 has been shown to form globular structures without
6

fibers in physiological buffer solution for up to 8 h and forms multimeric channel−like structures
in a planar lipid bilayer [47]. Petkova et al. have shown a full−length Aβ fibrils consisting of
anti−parallel β sheets and β hairpin (around residues 24 to 29) with a bend in residues 23 to 26
[48]. Gremer et at. have revealed a 4 Å resolution cryo−EM structure of Aβ1−42 fibrils having
LS−shaped topology [49]. On the other hand, Aβ1−40 is a truncation mutant obtained by deleting two of the neutral, non-polar aliphatic residues, Isoleucine and Alanine from the C−terminus.
This peptide has been shown to have disorder regions, β−sheets and a bend in backbone facilitating side−chains interactions [41]. The hydrophobic interactions are the major causes of amyloid
fibrillization. Aβ1−40 has been reported to spontaneously associate with anionic liposomes in helical structures and then it converts into β−sheets. This model assumes that β−sheet structure will
form disordered regions, and then it will later unwind the membrane−stabilized helical structure
[50].
Aβ25−35 , sequence Ac−GSNKGAIIGLM−NH2 , a proteolytic fragment of amyloid beta (Aβ1−42 )
has been reported to be the most active among several Aβ variants. It has a very high number
of hydrophobic residues and is the shortest fragment. Hence, it has been at the center of focus
because of its strong cytotoxicity despite being less abundant [51, 52, 53, 54, 55, 56, 57, 58, 59]. It
is also believed that they can form β−sheet aggregates and show similar mechanism of toxicity as
full length peptides through DNA damage and apoptosis [60, 61]. It has been shown that cytotoxic
effect of Aβ25−35 is linked to mitochondrial membrane damage, oxidative stress, cytochrome c
release and apoptotic cell death [59, 62, 63, 64]. While Aβ25−35 promotes the expression of protein
linked to mitochondrial permeability transition pore [65, 66], it also binds to the membrane and
forms ion−conducting pores [34, 36, 67, 68, 69, 70]. This peptide also forms voltage dependent
channels in the membrane with both cationic and anionic permeability in the order Ca2+ > K+
≥ Na+ > Cl− [67, 69]. In addition to this, Aβ25−35 tested on cultured neurons caused maximum
increase in intracellular Ca2+ close to the full length Aβ1−42 [70].
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This peptide is also reported to assume mixed α−helix/β−sheet structures in aqueous buffer and
β−turns and β−sheet structures at moderate and higher concentration respectively in anionic lipid
vesicles [71, 72, 73] with peripheral membrane binding in contrast to membrane insertion activities [74, 75, 76, 77]. Solid state NMR shows that organic phase mixing gives deeper insertion of
peptide compared to preformed vesicles [78]. Similarly, neutron diffraction data suggests larger
fraction of membrane inserted Aβ25−35 than peripheral for neutral membranes compared to negative membranes [79]. It undergoes transition from random−coil to β−sheet structures much
faster depending on the environmental cues [80]. Despite of all these experimental evidences for
membrane binding and insertion of Aβ25−35 , the molecular basis of membrane pore formation and
underlying structural changes are still elusive.
The peptide pEAβ3−42 is derived by deleting two N−terminal residues: aspartic acid (D) and
alanine (A) and catalyzing the cyclic reaction by using glutaminyl enzyme to convert glutamic
acid (E) to pyroglutamic acid (pE). The neuritic plaques consists of up to or even higher than 50 %
of pEAβ3−42 [81]. It is more hydrophobic than Aβ1−42 due to loss of negative charges and the
presence of lactum ring in the pE residue. Because of this, pEAβ3−42 has faster kinetics of self
assembly and aggregates much faster and acts as a seed for Aβ aggregation [82]. This will result
in increased interactions with lipid membrane. Large membrane inserted oligomers are reported to
induce increased pore activity while adsorbed oligomers produce little or no significant structural
damage [83]. Hence membrane inserted species are supposed to be the primary species responsible
for membrane permeabilization.
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2.3

Membrane Pores and Associated Neurotoxicity

2.3.1

Calcium Dysregulation

The dysregulation of calcium plays a key role in AD pathology. The level of intra−cellular calcium
is believed to control many aspects of neuronal physiology. The calcium signaling by neurons
controls many cellular processes including synaptic networks [84, 85]. The calcium hypothesis
as shown in Fig. 2.1, is one of the most convincing arguments of AD pathology. The plasma
membrane is always under a Ca2+ concentration gradient. The concentration of calcium in the
cytosol at minimal neuronal activity is about 0.2 µM while the outside calcium is roughly 1 mM
(almost 5000 times that of cytosol).

Figure 2.1: Calcium dysregulation in Alzheimer’s disease [85].
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There are growing evidences that Aβ oligomers bind to the membrane, forms pores/channels and
dysregulates Ca2+ level. This dysregulation is considered to cause neurodegeneration by triggering
signaling cascade in Alzheimer’s disease. It increases neuronal excitation which triggers aberration
of neuronal network, neuronal dysfunction and cell death. In addition, activation of calcineurons
(CaN) and calpains causes long term potentiation (LTP), long term depression (LTD), modification
of neuronal cytoskeleton, synaptic loss, neuritic atrophy, apoptosis and finally Alzheimer’s disease
[85].

2.3.2

Cholesterol Metabolism

The concentration of cholesterol in neuronal membranes has a profound role in membrane pore
formation activities of Aβ peptides especially because its dual role which can interact both with
peptide and lipid membrane depending on concentration. Cholesterol is the most predominant
sterol in the neuronal membranes, concentrated in sphingolipid islands called “lipid rafts”. Rafts
can form only in the outer leaflet of the membrane as the raft composition in the inner leaflet is not
possible. They can be very diverse in terms of their function, size, lifetime and composition. They
are several angstrom thicker than rest of the bilayer. It is related to lipid fluidity, receptor function,
endocytosis, enzyme activity, etc. Glial−derived APOE, a pathological chaperone, is the main
cholesterol transporter in the brain [86]. Membrane cholesterol, which regulates Aβ production
and oligomerization, plays a key role in this process [87]. Cholesterol binding to Aβ may play a
role in Aβ aggregation and cytotoxicity of the peptide, especially with elevated level of cholesterol
and its oxidized form [88, 89]. Cholesterol binding region of APP has been shown to encompass
Aβ25−35 by nuclear magnetic resonances [90]. Di Scala et al. [28] reported the fragment of residues
22 to 35 of Aβ is a potential cholesterol binding motif with Val−24 and Lys−28 being very critical
for binding that could facilitate the insertion of β−amyloid peptides or amyloid pore/channel
formation in cholesterol−rich membrane domains. Cholesterol has been observed to induce a
10

tilted α−helical topology of Aβ22−35 with hydrogen bonding between Asn−27 and Lys−28, a
key step in the oligomerization of eight Aβ22−35 /cholesterol sub−units to form a perfect annular
channel. Xiang et al. reported that increased cholesterol level promotes the binding of Aβ to the
lipid bilayer [87]. Several species of Aβ have been reported to interact with cholesterol at much
higher degree than POPC [34, 35, 36, 91, 92]. This may be the reason of enhanced neurotoxicity
of Aβ in presence of cholesterol [56, 93, 94]. It has also been reported that competitive interaction
of cholesterol with Aβ1−42 prevents its aggregation and β−sheet formation and hence inhibiting
the membrane disruption activities [95, 96]. Cholesterol was also shown to suppress the toxicity
of Aβ25−35 by hindering the formation of pathogenic aggregates [97]. Dual role of cholesterol
i.e. direct interaction with Aβ25−35 at low concentrations and membrane stiffening effect at high
cholesterol has also been reported [98]. However, the mode of interactions between cholesterol
and Aβ are still elusive.
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CHAPTER 3: MATERIALS AND METHODS

3.1

Materials

The following chemicals are used in this work. Lipids and cholesterol are ordered from Avanti
Polar Lipids (Alabaster, AL). Salts, chemicals, buffers and Ca2+ ionophore 4−Br−A23187 are
from Fisher Scientific (Hanover Park, IL) and Sigma−Aldrich (St. Louis, MO). We ordered all
peptides including those truncation variants for FRET studies (synthetic unlabeled) from Peptide
2.0 Inc (Chantilly, VA, USA) and 13 C and 15 N−labeled ones from Innovagen (Lund, Sweden) and
rPeptide (Bogart, GA, USA). For the synthesis of 13 C, 15 N−uniformly labeled full length Aβ1−42 ,
labeled amino−acids were purchased from Cambridge Isotope Laboratories, Inc. (Tewksbury,
MA) and sent to Peptide 2.0 Inc (Chantilly, VA, USA). Quin−2 was bought from EMD Chemicals
(San Diego, CA).

3.2

3.2.1

Methods

Fluorescence Spectroscopy

Fluorescence spectroscopy is a widely used technique to study protein folding and aggregation,
peptide−membrane interactions, membrane dynamics and many more. Jablonski diagram Fig. 3.1
can be used to explain fluorescence spectroscopy. Electrons can be excited by irradiating molecules
with light. They stay in the excited state some time and then return back to the ground state. This
process results in light emission, called luminescence. The singlet electrons (excited to singlet
state, S1 , S2 with opposite spin) can return quickly to the ground state by emitting photon called
fluorescence which usually lasts 10 ns. However, if excited electron happens to be in triplet state

12

Figure 3.1: Schematic diagram of fluorescence and phosphorescence phenomena.

where electrons have same spin as ground state, they can not come to the ground state easily and
they have to spend some time through some non−radiative processes. They spend longer time in
those states and finally come to ground state by emitting photons, a process called phosphorescence. Aromatic compounds are well−known for fluorescence. Transition of an electron from
the ground state to the excited state creates a large, transient dipole moment, which interacts with
the surrounding polar solvent (water) and reorients solvent molecules, an effect known as solvent
relaxation. Thus, before returning back to the ground state, the excited electron loses some energy and therefore the emission occurs at a larger wavelength, corresponding to smaller energy
compared to excitation. This shift is known as Stokes shift. Emission spectra and Stoke’s shift
can be used to derive the molecular information, solvent polarity, effect of temperature, and phase
transition in membranes.
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Figure 3.2: Chemical formula of Quin−2 tetrapotassium salt.

Most of the fluorescence assays in this study were done using Quin−2 with structure as shown in
Fig. 3.2. Detailed experimental procedures are described in the protocol by Tatulian et al. [99].
Briefly, Quin−2 loaded vesicles were prepared using the method of extrusion. The Quin−2 was
excited at wavelength of 339 nm and emission was observed around 492 nm. Fig. 3.4 explains
the basic steps for the preparation of desired Quin−2 loaded lipid vesicles. In order to mimic
the most common features of lipid membrane, our experiment focused in three main lipids POPC,
POPG and cholesterol as shown schematically in Fig. 3.3. First, we mixed different components of
lipids as desired in chloroform in a glass vial. Then, we dried the mixture by using gentle nitrogen
stream, leave in a desiccator for half an hour before vortexing in a desired buffer. The buffer used
is called inside buffer and contains 6 mM Quin−2, 20 mM Tris−HCl with pH 7.2 and different
concentrations of KCl as required by the experiment. The vortexing of lipid in buffer produced
multilamellar vesicles (MLVs). These MLVs were then extruded through 100 nm polycarbonate
membrane to get large unilamellar vesicles (LUVs) loaded with Quin−2. Desalting column as
shown in Fig. 3.6 was used for the removal of excess Quin−2 outside the vesicles. Osmotic
pressure was balanced across the vesicles membrane by using desired ingredients in the buffer.
The working lipid concentration was set at 5 mM. This was done by the use of calibration curve
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obtained from light scattering technique [100, 101].

Figure 3.3: Membrane lipid components used in the study: POPC (neutral or zwitterionic lipid),
POPG (negative lipid) and cholesterol (non−ionic sterol).

Jasco J−810 spectropolarimeter was used to detect permeation effect of peptide in the membrane.
To describe it briefly, using Quin−2 loaded vesicles in quartz cuvette, emission spectra (450 to
600 nm) were observed for about 20 min using the excitation wavelength of 339 nm. The change
of fluorescence over time was monitored to discover the mechanism of Ca2+ transport into the
vesicles. Control experiments were also carried out using blank buffer (negative) and ionophore
(positive). Temperature was set at 25 ◦C throughout the experiments. To find the structure of
peptide in the membrane, CD measurements were also recorded in the same sample. Using microelectrophoresis, the mode of peptide binding to the lipid membrane was investigated under various
conditions using the detail procedure given by Kandel et al. [101].
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Figure 3.4: Preparation of Quin−2 loaded unilamellar vesicles through extrusion.

Figure 3.5: Chemical structure of Laurdan.

We measured the generalized polarization (GP) of Laurdan (formula as shown in Fig. 3.5), incorporated in lipid vesicles at 1 mol % to analyze the membrane fluidity. The excitation wavelength
was at 360 nm and emission spectra were monitored between 380 and 580 nm. The emission spectra were found shifting depending on membrane fluidity which was then translated into generalized
polarization defined as
16

Figure 3.6: Schematic diagram showing how to remove Quin−2 present outside the vesicles by
using desalting column.

GP =

3.2.2

(F435 − F500 )
(F435 + F500 )

(3.1)

Circular Dichroism

Circular Dichroism (CD) is another great ultraviolet absorption technique to identify the secondary
structure of protein. It works under the principle of differential absorption of circularly polarized
light in two different directions as shown in Fig. 3.7. It uses an UV light source which is converted
into circularly polarized light (CPL) once it passes through photo−elastic modulator (PEM). When
an optically active molecule i.e. chiral center interacts with this CPL, there will be different amount
17

of absorption of right and left−polarized light and hence results ellipticity graph that will identify
the secondary structures of that molecule. This technique has advantages like it can be used for
so many different conditions, native or non−native proteins and disadvantages are it doesn’t give
very good resolution because of signal overlapping and strong light scattering in far UV region.

Figure 3.7: Schematic diagram of CD spectroscopy.

CD data were normalized using cell path length l, number of residues nr , molecular weight M and
concentration c of the sample using the Eq. 3.2.


θmr = θd


M
,
clnr

where θmr is molar ellipticity per residue and θd is degree ellipticity.
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(3.2)

Figure 3.8: CD spectra of β−sheet (blue), α−helix (black) and random coil or unordered (red).

In this work, CD spectra were recorded in a cuvette (4 mm × 4 mm) on the J−810 spectropolarimeter. Depending on the sample conditions, smaller path−length cuvettes 1 mm and 0.5 mm
have also been used for precision and accuracy. Some typical CD features are shown in Fig. 3.8.

Table 3.1: CD Signals of Some Common Secondary Structures
Secondary Structure

Positive Peaks

Negative Peaks

α−Helix

194 nm

222 nm, 208 nm

β−Sheet

195 nm

216 nm

β−Turns

195 nm

208 nm

Disordered Structure

215 nm

195 nm
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3.2.3

Fourier Transform Infrared Spectroscopy

This is a very sensitive tool to monitor protein conformations. It covers wide range of frequencies
but mostly used in amide−I region because of exceptional sensitivity to the secondary structures.
The frequency at which a molecule absorbs light depends on the formula and functional group
which are different in different molecules. We can also study proton−deuterium exchange using
FTIR. There is no light scattering problem in this technique as it is in infrared region [102]. The
simple FTIR setup is show in Fig. 3.9. It has mainly three parts, light source (IR), Michelson
interferometer with beam splitter and a detector [102]. The splitter splits 50 % of incident light,
half goes to rotating mirror and half to other static mirror. They again recombine in the beam

Figure 3.9: Schematic configuration of FTIR spectroscopy [102].
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splitter to produce interference. For constructive interference, ∆l = mλ and for destructive interference, ∆l = (m + 12 )λ, where m is any integer. Fourier transform is performed on the interferogram to produce transmission spectrum. It will be convenient to convert the transmission into
absorption spectrum using Eq. 3.3. Some of the FTIR peaks are shown in Table 3.2 taken from
[102].




Ts
A = −lg
,
Tr

(3.3)

where Ts and Tr are sample and reference transmissions respectively.

Table 3.2: FTIR Wavenumbers of Some Secondary Structures in H2 O and D2 O
Secondary Structure

WH2 O (cm−1 )

WD2 O (cm−1 )

α−Helix

1658 − 1647

1655 − 1638

Parallel β−Sheet

1638 − 1632

1636 − 1630

Antiparallel β−Sheet

1638 − 1632 (strong) and

1636 − 1630 (strong) and

1695 − 1675 (weak)

1680 − 1670 (weak)

Intermolecular (aggregated) β−Sheet

1627 − 1615

1625 − 1613

β−Turns

1685 − 1655

1675 − 1640

γ−Turns

1690 − 1650

1690 − 1650

To perform FTIR measurements, 75 µL of sample in 10 mM Na,K−phosphate buffer, pD 7.2 was
used in between two CaF2 window. A Teflon spacer of thickness 50 µm was also used between
them. Vector−22 spectrometer (Bruker Optics, Billeraca, MA, USA) was used for the measurement. This spectrometer has a Hg−Cd−Te detector which has to be cooled by using liquid nitrogen. The data were acquired at 2 cm−1 resolution at 25 ◦C and 1000 scans were co−added
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for better resolution. Blank buffers were used as references. The date analysis was performed
by converting the transmission spectra into absorption spectra for convenience [103]. We also
subtracted vapor whenever necessary. The data plotting and analysis was done using IGOR PRO
(https://www.wavemetrics.com/) and the GRAMS software (http://www.gramssuite.com).

3.2.4

Attenuated Total Reflection Fourier Transform Infrared Spectroscopy

ATR−FTIR is a surface sensitive substitute for direct FTIR when the sample is not transparent.
This technique is basically used to study parameter defining lipid order, lipid and peptide orientations, and so on. This technique is especially useful as sample can be analyzed directly without any
further preparations. Fig. 3.10 shows the basic ATR−FTIR components. The working principle
of this technique is based on production of evanescent wave as a result of total internal reflection.
Germanium is used as an internal reflection element (IRE) to serve this purpose [102].

Figure 3.10: Schematic diagram of ATR−FTIR spectroscopy [102].
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To perform ATR−FTIR measurements, the peptide Aβ25−35 was incorporated into lipid membrane
multilayers. For this, HFIP solutions of peptide and chloroform solutions of lipids were mixed
in the ratio P : L = 1 : 15, the lipid components being the same as used in vesicles leakage
experiments i.e. P OP C : P OP G : Chol = 0.3 : (0.7 − xchol ) : xchol . The sample was then
spread on a germanium plate (5 cm × 2 cm × 1 cm) with a cut at the 2 cm side at an angle of 45◦
aperture. The sample was air−dried and then desiccated for 1 h. ATR system (Buck Scientific,
East Norwalk, CT, USA) was assembled into Victor−22 FTIR spectrometer for measurement.
The sample was purged using dry air for 15 min before acquiring transmission spectra. The data
were recorded at 2 cm−1 resolution at two different polarizations: parallel (k) and perpendicular
(⊥). The sample was then saturated with D2 O vapors using a chamber at ∼ 90 ◦C and the same
measurement was done. Finally, another similar measurement was carried out using buffer of
50 mM NaCl, 50 mM Na,K−phosphate in D2 O, pD 7.2. The references used were the transmission
spectra of germanium plate and that of pure multilayer spectra without peptide.

3.2.5

Introduction to Forster Resonance Energy Transfer

Forster resonance energy transfer (FRET) or simply (RET) occurs between a fluorophore and some
other molecule when they happen to be within a certain distance where the emission spectrum of
the donor overlaps with the absorption spectrum of the acceptor [104]. In this situation, the excited
energy from the donor will transfer into the acceptor accompanied by enhancement in the emission
spectrum of the acceptor. These are the events occurring in the excited states of molecules. The
FRET transfer efficiency is determined in terms of distance Ro between them and the degree of
spectrum overlap [106]. The rate of energy transfer depends on the distance between donor and
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acceptor and is given by

 6
1 Ro
kt (r) =
τD r

(3.4)

where r is the distance between donor (D) and acceptor (A).
Similarly the energy transfer between the donor and acceptor pair is given by

E=

Ro6
Ro6 + r6

(3.5)

Figure 3.11: Figure showing overlapping of emission spectra of donors and acceptor for FRET.
Abbreviations: DE (Donor Emission), AA (Acceptor Absorption), AE (Acceptor Emission).
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The Forster distances, fortunately are comparable to the size of macromolecules. They are in the
range of 30 Å to 60 Å. This has inspired people to use these energy transfer phenomena as a tool
to measure distance between two different sites in a given molecule [105].

Table 3.3: Excitation Wavelength, Emission Wavelength and Quantum Yield of Three Aromatic
Residues in Water (pH 7.0), Taken from [106] and Corresponding Values Under Our Experimental
Conditions
Amino acid

λex (nm)

λem (nm)

λexp
ex (nm)

λexp
em (nm)

λopt
ex (nm)

Quantum Yield

Phenylalanine

260

282

265

290

220

0.02

Tyrosine

275

304

278

308

−

0.14

Tryptophan

295

353

0.13

295

−

0.13

In this work, will monitor the energy transfer between phenylalanine (Phe or F) as donor and tyrosine (Tyr or Y) as acceptor. The three fluorescent residues namely phenylalanine (Phe), tyrosine
(Tyr) and tryptophan (Trp or W) have their quantum yield in increasing order with Y and W having
similar yield. The fluorescence emission from higher yield residues would overshadow the weakest
emission spectrum coming from phenylalanine. Fortunately, we do not have tryptophan in Aβ1−42
and hence in any other Aβ variants peptide. We do have tyrosine (Y) in the sequence which would
still act like tryptophan (W) in terms of quantum yield compared to phenylanaline (F). Hence, we
have to make sure we are not directly exciting tyrosine while exciting phenylalanine. Normally,
this is always the case as they have very similar excitation wavelength around 260 nm and 275 nm
as shown in Table 3.3. This selective excitation can be achieved by manually optimizing the excitation wavelength and at the same time looking into the corresponding emission spectrum of
tyrosine. These excitation wavelengths can vary slightly depending on temperature, sample condition and solvent polarity. The optimized values for excitation and emission wavelengths of F and
25

Y, and the optimal excitation wavelength of F without exciting Y i.e. λopt
ex under our experimental
conditions are as shown in Table 3.3.
For this reason, we have to optimize the excitation wavelength for phenylalanine and tyrosine in
the entire region of excitation and emission and come up with a particular excitation wavelength
λex that will only excite phenylalanine but not tyrosine in the mixture of these fluorescent amino
acids. We optimized that λex and obtained 220 nm as the optimal value. There will always be some
residual excitation which can be subtracted in terms of difference spectrum (DS) defined as
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DS = 2Fxy
− (Fx220 + Fy220 )

(3.6)

where Fxy denotes emission spectrum of mixture of two peptides say x and y and Fx or Fy denotes
individual peptide emission when excited at 220 nm. The factor 2 is for dilution correction when
two equimolar mixtures are mixed together.
The sample preparation for these FRET experiments was done as described below. Stock solutions
of desired peptides at 100 µM concentration were prepared in HFIP and stored in refrigerator until
use. The desired peptides, either individual or equimolar mixture were transferred into a glass vial,
dried with stream of nitrogen and desiccated for 1 h to remove any residual solvent present. The
sample was then suspended in desired buffer (25 mM NaCl, 25 mM Na,K−phosphate in H2 O, pH
7.2) so as to make the working concentration of 100 µM. During this suspension process, ThT
was also incorporated at 20 µM concentration. The dilution correction was made in the case of
equimolar mixture. The measurement was done in Jasco J−810 spectropolarimeter using a 4 mm
path length quartz cuvette as usual.
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3.2.6

Principles of Solid State Nuclear Magnetic Resonance

This is one of the most advanced techniques that applies to systems with non zero nuclear spin.
Unfortunately, most of the naturally occurring isotopes have no magnetic moment except proton
1

H. Nuclei of odd numbered−atoms possess both spin and magnetic moments. Most of biological

protein samples are diamagnetic materials. In such materials, the magnetic moments are randomly
oriented in absence of magnetic field giving no net magnetization. However, when magnetic field
is applied to this system, the nuclei interact with the field and align themselves either along the
field or opposite to the field. Boltzmann factor e−µH/kT determines the number of population of
these states. For a given temperature T and magnetic field H, there will be a resultant magnetization in the direction of field as a result of the transitions induced. When another radio frequency
field is applied, it will flip the magnetization by desired angle. Once the pulse is removed, the
magnetization starts to freely relax back to the original direction. This decaying magnetization
will induce an rf current at the Larmor frequency.
Nuclear spin I is a unique feature of a given nucleus. Because electrons are spinning around the
nucleus, they behave like small molecular magnets. For a nucleus with even number of protons and
neutrons, the nuclear spin will be zero. Nuclei having sum of protons and neutrons odd will have
half integer spin like 1/2, 3/2, 5/2 and so on. If the number of neutrons and number of protons
are both odd, it will give integer spin like 1, 2, 3 and so on. The interaction of nuclear spin with
external magnetic field is defined in terms of a number m called magnetic quantum number written
as

m = 2I + 1

This magnetic quantum number will define different energy splitting in presence of external mag27

Figure 3.12: Splitting of spectral lines in presence of external magnetic field.

Figure 3.13: Free induction decay and corresponding signal in frequency domain.
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netic field as shown in Fig. 3.12.
NMR signal has a characteristic shape and frequency as a result of free precession of magnetic
moment. The decay of NMR signal is also called free induction decay (FID). This can be Fourier
transformed into frequency domain signal as shown in Fig. 3.13. The effect of static field can be
screened by working in a rotating frame about the static field at the nuclear Larmor frequency. The
magnetic resonance frequencies for nuclear spins lie in the radio frequency region (electrons spin
resonance in microwave region) and hence the process is also called radio frequency spectroscopy.
Due to the orbital motions of electrons, they produce a small magnetic field in the presence of an
external magnetic field, and incur a small shift to the actual field experienced by the nucleus. This
gives rise to a small shift to the resonance frequency of the nucleus. As the electron orbitals are
associated with the chemical environment of the element, this shift is a signature to the chemical
bonding and is called chemical shift or chemical shielding denoted by (δ). It is measured in parts
per million (ppm) and is defined as

δ=

ν − νo
× 106 ,
νo

(3.7)

where ν is for the sample and νo for the reference. A number of compounds can be used as
standards e.g. tetramethylsilane (TMS) for 1 H and 13 C nuclei and so on.
Just like a dipolar moment, the external field H will exert a torque on the magnetic moment µ of
the nucleus given by

dJ
= µ × H.
dt
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(3.8)

Magnetic moment and angular momentum vectors are related as

µ = γJ ,

(3.9)

where γ = (ge/2mc) is the gyromagnetic ratio of the given nucleus and depends on mass of the
nucleus, g is the g−factor and is approximately 2. Some important values are given in the Table
3.4.

Table 3.4: Parameters of Some Important Spin 1/2 Nuclei
Nucleus
1

H

Resonance (MHz) at 14.1 T

Natural abundance

Gyromagnetic ratio (MHz T−1 )

599.834

99.998 %

42.578

13

C

150.845

1.121 %

10.709

15

N

60.834

0.453 %

−4.312

242.938

100 %

17.24
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P

From Eqs. 3.8 and 3.9, we have

dµ
= µ × (γH) = µ × ω.
dt

(3.10)

The equation 3.10 tells that the magnetic moment vector precesses around magnetic field direction
at an angle θ generating a cone. This precession frequency which is needed for magnetic resonance
absorption is called Larmor’s frequency ωo given by the Eq. 3.11. This equation tells that it
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requires higher magnetic field to get stronger resonance for a given isotope.

ωo = γHo .

(3.11)

After the pulse is removed, the magnetization decays as the system comes back to equilibrium. The
magnetization will start dephasing in x−y plane because of the field inhomogeneity and spin−spin
relaxation while it returns gradually to thermo−equilibrium distribution along z direction following spin−lattice relaxation. Bloch equations can be used to describe the recovery phenomena:

Mo − Mz
dMz
=
+ γ(M × H)z
dt
T1

(3.12)

Mx
dMx
= γ(M × H)x −
dt
T2

(3.13)

dMy
My
= γ(M × H)y −
,
dt
T2

(3.14)

The decay rate is ∼ e−t/T2 and the recovery is given by


− t 
Mz = Mo 1 − e T1 .

(3.15)

For the ssNMR experiment, two different sample preparation methods were used, aqueous phase
mixing and organic phase mixing [107]. In the first procedure with peptides Aβ1−42 and pEAβ3−42
that are 13 C, 15 N−segmentally labeled at 16 K17 L18 V and 36 V37 G38 G39 V, each labeled peptide sam-
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ples were reconstituted in lipid membrane with 60 % POPC, 30 % POPG and 10 % cholesterol in
the peptide to lipid molar ratio of P : L = 1 : 25. Stock solutions of peptides each (∼ 6 mg) were
prepared in 250 µL of HFIP. All the lipid stocks (POPC, POPG and cholesterol) at 44.3 mM concentration were prepared in chloroform. Desired volumes of POPC, POPG and cholesterol were
mixed in a glass vial and then transferred to the stock peptide. The mixture was then vortexed for
5 s to 10 s to ensure homogenous mixing. The solvent was then dried using nitrogen stream and
then desiccated for 30 min to remove any residual solvent. Final suspension was prepared in 2 mL
phosphate buffer (10 mM Na,K−phosphate, pD 7.2) by vortexing the sample vigorously for 5 to
10 min. This resulted in peptide reconstituted multilamellar vesicles (MLVs). These MLVs were
extruded using 200 nm polycarbonate filter as described earlier [101]. The extruded sample was
then ultra−centrifuged at 200 000 g for 3 h at 24 ◦C using Beckman Coulter Optima TLX benchtop
Ultracentrifuge. The supernatant was carefully removed and the pellet was transferred to 3.2 mm,
36 µL (MAS) rotor for NMR measurements. The peptide concentration in supernatant and the
pellet was measured using NanoDrop spectrophotometer before packing into the MAS rotor.
In the second set of sample preparation, method of organic phase mixing was used. The purpose was to enhance the signal noise and spectral quality without changing the final conditions
of peptide−incorporated lipid vesicles [107]. In this method, desired concentration of peptide
(especially used for pEAβ3−42 that is
15

13

C,

15

N−segmentally labeled at

36

V37 G38 G39 V and

13

C,

N−uniformly labeled Aβ1−42 ) in HFIP and lipids in chloroform were mixed gently in a glass

vial so that the final peptide to lipid molar ratio became P : L = 1 : 25. The mixture was then
dried using nitrogen stream. Then, the sample was placed in a desiccator overnight to make sure all
organic solvents were evaporated. Finally, the whole sample was again dissolved in cyclohexane.
After it was completely dissolved in cyclohexane, we lyophilised the sample for 12 h. The final
lyophilized sample was then packed into 3.2 mm, 36 µL (MAS) rotor followed by hydration using
27 µL of buffer for NMR measurements.
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Figure 3.14:

Schematic diagram of DARR mixing.

This resonance can connect either

intra−residues or inter−residues depending on mixing time.

NMR spectra were acquired on a 600 MHz (14.1 T) Agilent spectrometer with a triple resonance
3.2 mm magic angle spinning (MAS) probe at 13.5 kHz MAS. Two−pulse−phase−modulated
(TPPM) [108, 109] decoupling of 95 kHz was applied on proton. The rf fields during cross polarization (CP) [110] were 50 kHz and 36.5 kHz on carbon and proton respectively. In two−dimensional
carbon−carbon correlation spectra acquisition, 50 ms dipolar−assisted rotational resonance (DARR)
[109] was used with indirect dimension spectral width of 33 kHz and complex points 128. All the
measurements were done at 4 ◦C to minimize the effect of internal heating to the sample due
to radio frequency fields, especially coming from the long decoupling in salty hydrated sample.
Depending on assignments, sample was also sent to National High Magnetic Field Laboratory,
(NHMFL), Tallahassee, FL where measurements were carried out on a Bruker, 800 MHz mag33

net. The spectra were processed using NMRpipe and plotted with NMRFAM−SPARKY [111]
and UCSF−SPARKY3 (University of California, San Francisco). The chemical shift values were
referenced based on tetramethylsilane (TMS).
Solid state NMR is different than liquid state NMR because the anisotropy will not average out
from the molecular tumbling unlike in the liquid phase. And because of this anisotropy, the resonance line is broadened and resolution will be deminished. We can effectively suppress those
anisotropies by spinning the sample at a fixed angle called magic angle 54.7◦ and decoupling the
protons from carbons. Because most of the naturally occurring isotopes like
netic moment, they have to be isotopically replaced by active nuclei like

13

12

C have no mag-

C and

15

N which can

be achieved either by recombinant protein synthesis or by expression and purification in bacterial
medium. To enhance sensitivity, techniques such as cross polarization (CP) are commonly used.
This technique has another advantage over direct excitation: it detects only rigid segments while
the direction excitation detects all possible signals rigid and flexible.
The initial sample and spectral quality can be checked using 1D CP MAS and 2D−CC dipolar
assisted rotational resonance (DARR) with different mixing times like 25 ms and 50 ms. Sequential assignment can be used to analyze secondary structures and dynamics. To check the signal
resolution, 2D−NCOCX and 2D−NCACX spectra can be acquired. If there are ambiguities in the
assignment, then 3D−NCACX and 3D−NCOCX can be performed which will most likely resolve
the congestion to identify the residues if the line width is near or less than 1 ppm. The longer
mixing times 2D and 3D experiments can be used to probe tertiary and quaternary constraints.
The qualitative distance constraints can be achieved by using PITHIRDS [112] and REDOR [113]
sequences.
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3.3

Theoretical Prospective of Membrane Binding and Pore Formation

Gouy−Chapman−Stern theory is used to analyze membrane binding parameters based on ζ−potential
measurement described elsewhere [114]. In what follows, a briefly summary of the theory is presented with symbols having their usual meanings. The total surface charge density in vesicle
membrane is written as

σ = σo + σb ,

(3.16)

where σo is the intrinsic charge density of lipid and σb is from peptide binding to membrane.
The Gouy−Chapman equation can be used to find total surface charge density σ (for 1 : 1 electrolyte) as

σ=

p




F ψo
8o RT Csh
,
2RT

(3.17)

The ζ−potential can be expressed as

ζ = ψo e−δ/λ ,

s
λ=

o RT
P 2 ,
zi Ci

F2
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(3.18)

(3.19)

The bound surface charge density due to peptide σb is expressed as

σb =

ze[Pb ]
,
γ[L]Alipid

(3.20)

Membrane−binding is a bi−molecular process [117]. Following the theory described earlier [101],
the membrane binding isotherm can be written as



p
√
ze
F ψo
2
σo +
(a − a − b) = 8o RT Csh
,
γ[L]Alipid
2RT

(3.21)

Using Eq. 3.21, with experimentally determined values of ζ−potential, we constructed theoretical
binding isotherms for various aggregations numbers like z = 1, z = 4, and z = 8. Finally, the
membrane binding and pore formation mechanism was analyzed based on theoretical framework
previously described [100].

3.4

3.4.1

FTIR Data Analysis

Secondary Structures Determination

FTIR and ATR−FTIR techniques can be used for the analysis of the secondary structures of peptide incorporated in lipid vesicles or in supported lipid bilayers. The detail procedure for structural
characterization is described elsewhere [102]. Briefly, to analyze the structure and orientation of
membrane−bound peptide, ATR−FTIR spectra were recorded at two different polarization, parallel (k) and then perpendicular (⊥). The spectra were then converted into polarization independent
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spectrum using the relation

A = Ak + GA⊥ ,

(3.22)

2Ez2 − Ex2
.
Ey2

(3.23)

where G is the scaling factor given by

G=

The polarization independent amide I area was determined by using the relation

ai =

ai,k + Gai,⊥
,
atotal,k + Gatotal,⊥

(3.24)

where atotal,k and atotal,⊥ are total amide I areas at k and ⊥ polarization respectively corrected by
subtraction of side−chain component.
The GRAMS software was used to do curve−fitting and to calculate fraction of secondary structure
by using the relation

ai

fi =


i

aα
α

+

aβ
β
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+

at
t

+

aρ
ρ

.

(3.25)

3.4.2

Orientation of Peptides

ATR−FTIR spectroscopy can be used to analyze the orientation of membrane−bound peptides.
For a given structure with a molecular axis, the orientation order parameter is defined as

S=

2B
,
(3hcos2 αi − 1)(B − 3Ez2 )

(3.26)

where, α = 38 to 40◦ for α−helix.
For lipid acyl chain in all−trans conformation, the angle between CH2 stretching vibrations and
the chain axis is 90◦ [102, 118, 119], hence from Eq. 3.26, we can write

S=

2B
.
(3Ez2 − B)

(3.27)

The angle S between the membrane normal and the molecular axis is given by

1
S = (3hcos2 θi − 1).
2

(3.28)

The β−strand orientation is more difficult to calculate unless strands are arranged in central symmetry about the rotational axis. Then, the orientation of the β−strands is given by [119]

1
2B
(3hsin2 βi − 1) =
.
2
2
(3hcos γi − 1)(B − 3Ez2 )

(3.29)

Knowing the angle γ between pore axis and membrane normal and the dichroic ratio Ri , we can
calculate the angle β, the angle between strand axis and the central axis of the pore.
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CHAPTER 4: RESULTS

4.1

Salt Dependent Membrane Binding and Pore Formation by Aβ25−35

In this section, the detailed analysis of Aβ25−35 binding to membrane and resulting pore formation
under various salt conditions and different lipid compositions is described. Several parameters
were calculated which enabled us to find the detail structure of the pore.

4.1.1

Aβ25−35 Peptide in Aqueous Buffer

Figure 4.1: FTIR (a) and CD (b) structures of Aβ25−35 in aqueous buffer. FTIR measurements
were done in buffer of 50 mM Na,K−phosphate, 50 mM NaCl, pD 7.2 and CD measurements
were carried out in Tris buffer (145 mM NaCl, 50 mM Tris, pH 7.2).

We used CD and FTIR to analyze the structural change of peptide in aqueous buffer (145 mM
NaCl and 50 mM Tris−HCl, pH 7.2). The CD data showed a gradual change of conformation from
unordered structure to type−I β−turn as we incubated the peptide in the buffer. In about 2.5 h, the
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transition saturated. FTIR data revealed that the initial structure was unordered and β−turns which
then changed to intermolecular β−sheet in about 15 min after putting in aqueous buffer (50 mM
NaCl and 50 mM Na,K−phosphate, pD 7.2) as shown in Fig. 4.1. These data suggest that Aβ25−35
assumes heterogeneous conformations, mostly of β−sheet and β−turn [101].

4.1.2

Binding of Aβ25−35 Peptide to Lipid Membrane

In order to understand the membrane binding mechanism, we used microelectrophoresis to measure ζ−potential of lipid vesicles before and after addition of peptide. The peptide was incubated for 2.5 h in aqueous buffer and added to anionic vesicles with composition 60 mol % POPC,
30 mol % POPG and 10 mol % cholesterol. This lipid composition makes the overall charge of the
membrane negative while peptide has a positive charge of Lys28 . When we increased the peptide
concentration, the negative ζ−potential of vesicles was reduced. This confirmed membrane binding as shown in Fig. 4.2. As we increased the concentrations of NaCl in the buffer, the peptide
binding and surface potential of vesicles were both decreased. This suggested an important role of
electrostatics in membrane−peptide interactions.
Using the data at different ionic concentrations, we found that vesicles had a layer of bound water
molecules which is consistent with a shear layer thickness of 3 Å [101]. Moreover, the saturation of
ζ−potential at higher concentration of peptide as shown in Fig. 4.2 (a − c) suggested that peptide
2

binding site has limited surface area available. Using cross sectional area 59 Å for POPC and
2

2

POPG and 23 Å for cholesterol [120, 121], we found that Alipid = 55.4 Å . The detail calculation
procedure is described in [101]. The binding curves for z > 8 went out of experimental range as
shown in Fig. 4.2 (a − c). This suggested that either there were no larger particles or they didn’t
bind to the membrane.

40

Figure 4.2: ζ−potential of lipid vesicles as a function of added peptide at different salt (NaCl)
concentrations: 10 mM (a), 30 mM (b), and 75 mM (c) in Tris−HCl buffer (20 mM, pH 7.2).
Solid, dashed and dotted lines represent theoretical plots for aggregation numbers of z = 1, z = 4,
and z = 8 respectively. The corresponding variation of binding constants (apparent) are shown in
panels (d − f ). The working lipid concentration is 0.2 mM with membrane molar composition of
60 % PC, 30 % PG and 10 % cholesterol.

This peptide Aβ25−35 has been shown to form soluble oligomers at shorter times [122]. The peptide
assemblies contained monomers to octamers during incubation in buffer. The number of lipids per
unit binding site NL and intrinsic dissociation constants KD were calculated using the surface
charge and area of lipid. We were able to calculate that 25 to 40 lipid molecules are required for
a monomer−binding site. This number was found to be directly proportional to the aggregation
number. Similarly, the dissociation constants for different species i.e. monomers, tetramers and
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octamers were calculated to be 2.5 × 10−5 M to 4.4 × 10−5 M, 1.6 × 10−4 M to 2.0 × 10−4 M and
4.2 × 10−3 M to 5.6 × 10−3 M respectively. The detail parameters are given in Table 4.1, 4.2, and
4.3 respectively.
The apparent binding constants corresponding to zeta potential measurements (a − c) were plotted
as shown in Fig. 4.2(d − f ). These constants were evaluated by using measured zeta potentials and
dissociation constants given in Table 4.1, 4.2, and 4.3. The binding constants are seen decreasing
with increasing salt concentrations. These apparent binding constants are higher for higher peptide
assemblies as shown in Fig. 4.2(d − f ). They are in range of data reported earlier [80].

Table 4.1: Binding Parameters Describing the Binding of Aβ25−35 to Lipid Vesicles for Aggregation Number z = 1
NaCl (mM)

σo (mC m−2 )

KD (M)

NL

10

−21.19

2.5 × 10−5

26.3

30

−22.70

2.5 × 10−5

40.5

75

−25.61

4.4 × 10−5

33.5

Table 4.2: Binding Parameters Describing the Binding of Aβ25−35 to Lipid Vesicles for Aggregation Number z = 4
NaCl (mM)

σo (mC m−2 )

KD (M)

NL

10

−21.19

1.6 × 10−4

105.1

30

−22.70

1.6 × 10−4

161.8

75

−25.61

2.0 × 10−4

134.0
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Table 4.3: Binding Parameters Describing the Binding of Aβ25−35 to Lipid Vesicles for Aggregation Number z = 8
NaCl (mM)

σo (mC m−2 )

KD (M)

NL

10

−21.19

5.6 × 10−3

210.2

30

−22.70

5.6 × 10−3

323.6

75

−25.61

5.6 × 10−3

268.0

4.1.3

Membrane Permeabilization Effect of Peptide

In this assay, we tested the effect of peptide on membrane permeabilization using anionic and
zwitterionic lipids. The peptide was first incubated in the same buffer for 2.5 h before adding to
the lipid vesicles. We first tested the controls, calcium ionophore as positive and buffer as negative.
Addition of ionophore resulted in a strong Quin−2 fluorescence while buffer alone didn’t cause
any fluorescence as shown in Fig. 4.3. This confirmed that our lipid vesicles system is intact
and fully functional. The effect of peptide at low ionic strength was over 50 % that of positive
control. The time constant was calculated to be 0.33 min to 1.67 min. The effect was greatly
reduced as we increased the salt concentration in the buffer. The rate constant reached over 30 min
with high salt concentration ≥ 180 mM. This confirmed again that the electrostatic screening is
the leading phenomena in these processes in which counterions collect in between the positively
charged peptide and negatively charged membrane and reduce the effective charge of attraction.
These data agree with earlier reported studies [80].
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Figure 4.3: Quin−2 fluorescence as a function of time due to influx of Ca2+ at different salt concentrations: 30 mM (a), 75 mM (b), 150 mM (c) and 180 mM (d). Squares, circles and triangles
represent P : L = 1 : 10, 1 : 5 and 1 : 3 and rhombs represent effect of ionophore as positive
control. The working lipid concentration is 0.2 mM with membrane molar composition of 60 %
PC, 30 % PG and 10 % cholesterol. All data are normalized to unity based on the maximum effect
of ionophore.

Based on the Quin−2 fluorescence assay experiment shown in Fig. 4.4, we can say that membrane
permeation effect of Aβ25−35 depends bi−phasically on ionic strength of the buffer. The rate
constant increased with increasing ionic concentrations of buffer up to 100 mM to 150 mM and then
decreased. This dual effect is the result of electrostatic screening from counterion accumulation.
At high ionic concentration, peptide−peptide interactions is dominant and peptide−membrane in44

Figure 4.4: Relative Quin−2 fluorescence intensity as a function of salt in buffer (a), single exponential rate constant as a function of salt in buffer (b), and second order rate constant of pore
formation as a function of salt in buffer (c). Solid (z = 1), dashed (z = 4) and dotted (z = 8)
lines represent theoretical isotherms respectively. The working lipid concentration is 0.2 mM with
membrane molar composition of 60 % PC, 30 % PG and 10 % cholesterol. Peptide concentration
is 66.7 µM.

Figure 4.5: Model of lipid vesicles with Quin−2 entrapped inside and illustration of membrane
permeation, pore formation, calcium influx and Quin−2 fluorescence enhancement.
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teractions is decreased. We identified two different pore populations. At low salt ≤ 50 mM, the
population consisted of 3 to 5 peptide units while at high salt concentrations ≥ 75 mM, 7 to 9
peptide units were found. The functional pores were oligomers of oligomers i.e. hexamers of
hexamers or octamers of octamers.

Figure 4.6: Size distribution of lipid vesicles as a function of peptide concentration shown using
dynamic light scattering. The working lipid vesicle concentration is 0.2 mM with membrane molar
composition of 60 % PC, 30 % PG and 10 % cholesterol.

Moreover, this assay also shows that the Quin−2 fluorescence Frel never reached the effect of Ca2+
ionophore as shown in Fig. 4.3. To validate this phenomena, we used dynamic light scattering
to find size distribution of vesicles in presence of peptide as shown in Fig. 4.6. The result is
highly poly−dispersed especially at higher peptide concentrations. The peak at about 130 nm is
the average vesicles size in absence of peptide consistent with earlier data [123, 124]. As we
increased the peptide concentration, the peak upshifted and other higher size peaks appeared due
to vesicles aggregation. In order to calculate the number of lipids per vesicles, we used lipid
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concentration 0.2 mM, vesicles diameter 140 nm, and area per lipid 0.554 nm2 and found that ≈
2.137 × 105 lipid molecules are required to build a vesicle. This corresponds about 0.936 nM
under our experimental conditions. If we consider the highest salt concentration of 300 mM NaCl
in buffer, the number of peptide assemblies per lipid vesicle would be 2540, 360 and 63 at lowest
concentration of peptide 2.38 µM, 0.337 µM and 0.059 µM for monomers, tetramers and octamers
respectively. At lowest concentration of NaCl, these number would be up to 7−fold greater. If
36 to 64 monomers are needed to form a fully functional pore, then we would not have all pores
functional [125]. Another reason might be because of incomplete targeting of lipid vesicles as
demonstrated for antimicrobial peptides earlier [61, 126, 127].
After analyzing these electrostatic effects coming from salt concentration in the buffer, we performed another different membrane binding assay in neutral membrane without negative lipid and
containing 90 mol % POPC and 10 mol % cholesterol only. We observed the ζ−potential of −6 mV
corresponding to a surface charge density of σo = −5.926 mC m−2 . Although one would expect at
least some non−negative value of this potential in this case (with neutral membrane and positive
peptide), our small negative value might be attributed to Cl− binding [114, 115, 116]. Moreover, the ζ−potential almost didn’t depend on peptide concentration and potential went positive at
≥ 40 µM of peptide as shown in Fig. 4.7. This would suggest weak peptide binding to zwitterionic membrane and peptide aggregation at high concentration. The Quin−2 fluorescence and rate
constants were found to be very low compared to similar system with 30 mol % POPG. The reason behind this may be that there is very little lateral mobility of peptide because of ionic and/or
hydrogen−binding in presence of POPG and hence less peptide−peptide interactions. In neutral
membrane, interaction of peptide with membrane is very insignificant. Similar effects have been
studied earlier [125, 128] for Aβ1−40 and Aβ1−42 . This again confirms that membrane binding of
Aβ25−35 is largely driven by electrostatics.
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Figure 4.7: ζ−potential of lipid vesicles as a function of added peptide concentrations with NaCl
salt of 75 mM in the buffer. Solid, dashed and dotted lines represent theoretical plots for aggregation numbers of z = 1, z = 4, and z = 8 respectively (a). Quin−2 fluorescence as a function
of time (b). Squares, circles and triangles represent P : L = 1 : 10, 1 : 5 and 1 : 3 and rhombs
represent effect of ionophore as positive control. The working lipid concentration is 0.2 mM with
membrane molar composition of 90 % PC and 10 % cholesterol that will behave as a neutral membrane.

4.1.4

Structure of Peptide in Lipid Vesicles

The CD spectroscopy has been used to assess the structure of peptide in the lipid membrane. The
spectra shows that at relatively low salt concentration, the peptide assumes β−sheet structure (ionic
strength up to 150 mM of NaCl in buffer). As the salt concentration in the buffer was increased
beyond that range, the peptide didn’t bind to the membrane and the structure remained the same as
in aqueous buffer as shown in Fig. 4.8. This effect can be explained in terms of the increasing role
of electrostatic screening with increasing salt concentration. Higher salt prevented the binding
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Figure 4.8: CD spectra of Aβ25−35 with (black solid) and without (gray solid) lipid vesicles at
different ionic strength: (a) 30 mM, (b) 50 mM, (c) 75 mM, (d) 180 mM, (e) 225 mM, and (f )
300 mM of NaCl. The second derivatives are shown with respective dotted lines with (black) and
without (gray) lipid vesicles. The working lipid concentration is 0.2 mM with membrane molar
composition of 60 % PC, 30 % PG and 10 % cholesterol.

of peptide to the lipid vesicles. At intermediate salt 50 mM to 150 mM, rate constant of pore
formation and transport of Ca2+ into the vesicles was the highest. This indicates that β−sheet
conformation of peptide forms the most efficient pore.
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4.2

Role of Cholesterol on Membrane Binding and Pore Formation by Aβ25−35

Cholesterol is a very important part of neuronal membranes and its concentration varies with different types of cellular membranes. It plays a very distinct role in membrane−peptide interactions
at different concentrations. To elucidate more on this complex behavior, we varied the concentra-

Figure 4.9: Quin−2 fluorescence as a function of time (due to influx of Ca2+ ) at different cholesterol concentrations: 0 % (a), 5 % (b), 10 % (c), 20 % (d), and 40 % (e). The lipid composition is
(0.7 − xchol ), 0.3, and xchol mol % of POPC, POPG and cholesterol with xchol varying from 0.00,
0.05, 0.10, 0.20, and 0.40 respectively. Squares, circles and triangles represent P : L = 1 : 10,
1 : 5 and 1 : 3 and rhombs represent effect of ionophore as positive control. The working lipid
concentration is 0.2 mM with buffer ionic strength of 75 mM. Graph (f ) represents increase in
Quin−2 fluorescence 2 min after the addition of peptide.
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Figure 4.10: Relative Quin−2 fluorescence (a), single exponential rate constant (b), second−order
rate constant of pore formation (c), affinity constant of peptide oligomers within the membrane
(d), and the number of oligomers in the pore structure (e) as a function of cholesterol. The lipid
composition is (0.7 − xchol ), 0.3, and xchol mol % of POPC, POPG and cholesterol with xchol
varying from 0.00, 0.05, 0.10, 0.20, and 0.40 respectively. The working lipid concentration is
0.2 mM and ionic strength of buffer is 75 mM NaCl.

tion of cholesterol in the vesicles within a nearly physiological range. Quin−2 loaded vesicles
with (0.7 − xchol ) mol % of POPC, 0.3 mol % POPG and xchol mol % of cholesterol with xchol
varying from 0, 0.05, 0.10, 0.20 and 0.40 were assayed with three different concentrations of
peptide as shown in Fig. 4.9. The relative fluorescence Frel was found to be directly proportional
to the peptide concentration as shown in Fig. 4.10 (a) indicating polymorphic nature of Aβ which
results in heterogeneous membrane bound structures [129, 130, 131]. It has been shown that the
incubation of Aβ25−35 in buffer for about 2.5 h resulted oligomers with up to 8 monomers [101].
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Figure 4.11: Light scattering of lipid vesicles before (gray) and after (black) addition of ionophore
or peptide in µM as shown in the legend at various cholesterol concentrations: 0 % (a), 5 % (b),
10 % (c), 20 % (d), and 40 % (e). The lipid composition is (0.7 − xchol ), 0.3, and xchol mol % of
POPC, POPG and cholesterol with xchol varying from 0.00, 0.05, 0.10, 0.20, and 0.40 respectively.
The working lipid concentration is 0.2 mM and ionic strength of buffer is 75 mM NaCl.

These are the most active species in terms of membrane pore formation. When these peptide
oligomers are added to the vesicles, they first bind to the membrane and then come together to
form a functional pore with different number of peptide units n. The detail parameters are listed in
Table B.4.
The role of cholesterol appeared to be complex as shown in Fig. 4.10. The values of ka and
Kp initially increased up to xchol = 0.05, dropped around xchol = 0.2 and again went up at
xchol = 0.4 as shown in Fig. 4.10 (c, d). The number of oligomers in the pore, n was found to be
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in between 6 to 8 at cholesterol levels of xchol = 0.0 − 0.1 and xchol = 0.4. The value decreased
to about 5 at xchol = 0.2 as shown in Fig. 4.10 (e). This result indicates that pore formation is
most effective by larger assemblies of peptide. This phenomena will be discussed later comparing
with the membrane fluidity experimental data. Fig. 4.11 shows an increase of light scattering
with addition of peptide which is directly proportional to concentration of peptide. This indicates
that vesicles are intact in presence of peptide. The increase in light scattering is due to vesicles
aggregation.

4.2.1

Structure of Peptide by Circular Dichroism

CD spectra showed that the peptide assumed β−turn (type−I) structure with minimum fraction of
β−sheet and α−helix at peptide to lipid ratio of 1 : 3, for cholesterol mol % from 0.00 to 0.20 as
shown in Fig. 4.12 (a, d). At xchol = 0.4, the α−helix component increased as shown in Fig. 4.12
(e). At lower peptide to lipid ratios of 1 : 5 and 1 : 10, α−helical fraction at 220 nm decreased
indicating β−sheet and β−turn structure.
The peptide structures shown by these spectra contain contribution from both membrane−bound
peptide and free peptide in aqueous buffer. The structural features of CD spectra is greatly affected
by the polarity of the environment. Because of poor resolution of these spectra and that the sample
contained both membrane bound and free peptide, we plotted the CD spectra of only membrane
bound peptide by subtracting the free peptide contribution from the total spectra as shown in Fig.
4.13. These data suggest that the membrane−bound peptide has β−sheet conformation that was
red−shifted because of polarity of the environment [132, 133].

53

Figure 4.12: CD spectra of Aβ25−35 peptide at different cholesterol concentrations: 0 % (a), 5 %
(b), 10 % (c), 20 % (d), and 40 % (e) in lipid vesicles with ionic strength of buffer 75 mM NaCl.
The lipid composition is (0.7 − xchol ), 0.3, and xchol mol % of POPC, POPG and cholesterol with
xchol varying from 0.00, 0.05, 0.10, 0.20, and 0.40 respectively. The working lipid concentration is
0.2 mM. Legend: P : L = 1 : 10 (gray), 1 : 5 (black dotted), and 1 : 3 (black solid).
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Figure 4.13: Original CD spectrum of Aβ25−35 peptide (a) with no lipid vesicles and (b)
membrane−bound peptide at various cholesterol percentages as shown in the graph. The ionic
strength of buffer is 75 mM NaCl and the working lipid concentration is 0.2 mM.

4.2.2

Effect of Cholesterol on Membrane Fluidity

Generalized polarization (GP) of Laurdan was used to monitor the fluidity of lipid membrane.
Without the cholesterol, Laurdan showed two emission peaks located at 435 nm and 500 nm. When
the cholesterol was added to the membrane, increasing up to 0.4 mol %, the 500 nm peak gradually
disappeared while the 435 nm component increased as shown in Fig. 4.14. This effect suggests
that membrane becomes more and more solid [134] in presence of cholesterol. Lipid membrane
was reported to transition from liquid−disordered phase (Ld ) to liquid−ordered phase (Lo ) with
increasing cholesterol [135] which should inhibit the membrane insertion effect of the peptide with
increasing concentration of cholesterol. Our data, however indicates more complex effect i.e. inter55

Figure 4.14: Membrane fluidity as measured by Laurdan fluorescence (a) and generalized polarization (GP) of Laurdan (b) at different cholesterol concentrations shown. The lipid composition
is (0.7 − xchol ), 0.3, and xchol mol % of POPC, POPG and cholesterol with xchol varying from 0.00,
0.05, 0.10, 0.20, and 0.40 respectively.

action of cholesterol with the peptide and then modulation of membrane by the cholesterol. Cholesterol interacts with the peptide directly at low concentration i.e. (xchol = 0.05) [34, 36, 91, 92].
This effect enhanced the membrane pore formation as indicated by increasing values of ka and
Kp . In this case, pore structure contained 8 oligomers, as shown in Fig. 4.10 (c − e). When the
cholesterol level was increased up to xchol = 0.2, it caused a decrease in all three parameters. This
may be explained by the fact that squeezing out of peptide assemblies occurred during membrane
transition to (Lo ) phase. After this point, once the cholesterol reached (xchol = 0.4), the membrane condensing effect of cholesterol saturated which resulted in disordered boundaries between
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phospholipid−rich and cholesterol−rich domains. This eventually promoted the peptide insertion
and hence pore formation as indicated by an increase in ka and Kp values as shown in Fig. 4.10
(c, d).

4.2.3

Determination of Peptide Structure Using ATR−FTIR Spectroscopy

In order to examine the secondary structure components, ATR−FTIR spectra of dry lipid sample
with embedded peptide were monitored. Data showed that most of the component as β−sheet
at 1630 cm−1 to 1628 cm−1 with other lower intensity components at 1660 cm−1 to 1654 cm−1 as
α−helix, 1644 cm−1 to 1642 cm−1 as irregular (unordered), 1700 cm−1 to 1670 cm−1 , as β−turns
or γ−turns and 1620 cm−1 to 1600 cm−1 are from the side chains [136]. The measurements were
also repeated using D2 O vapor and D2 O buffer as shown in Fig. 4.15. Although there was a
significant change in the structure between these three different conditions, β−sheet still remained
the dominant structures. In dry state, there was about 30 % of β−sheet component, 30 % to 40 %
of β−turns, 20 % of α−helix, and ∼ 10 % of irregular structure. Increase in β−turns can be seen
with higher cholesterol content.
As shown in Fig. 4.15 (b), after D2 O hydration, the β−sheet components increase and β−turns
decrease with increasing cholesterol [136]. In D2 O buffer at 5 % and 40 % cholesterol, component
of β−sheet jumped to 40 %, and β−turns decreased down to about 20 % as shown in Fig. 4.15 (c).
Interestingly enough, the membrane pore formation activity is maximal at xchol = 0.05 and 0.40.
This result indicates that Aβ25−35 should be in β−sheet conformation in order to form a functional
pore.
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Figure 4.15: Figure shows fractions of secondary structures of Aβ25−35 in lipid multilayers in dry
state (a), D2 O vapor (b) and D2 O buffer (c). The lipid composition is (0.7 − xchol ), 0.3, and xchol
mol % of POPC, POPG and cholesterol with xchol varying from 0.00, 0.05, 0.10, 0.20, and 0.40
respectively. The symbols used are α for α−helix, β for β−sheet, t for turn and ρ for irregular
structures.

4.2.4

Peptide Orientation and Lipid Order from ATR−FTIR Spectroscopy

The ATR−FTIR method was employed to monitor the order and orientation of peptide and lipid.
Data showed that most of the peptide in membrane was in β−sheet conformations. This tells us
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that we can model the pore as β−barrel−like structure. The angle between the β−strands and the
barrel axis was evaluated using the Eq. 3.29 with angle γ varying within some conceivable range,
0◦ to 20◦ . The possible values are shown in Table 4.4. The ATR dichroic ratio was calculated as
Rβ = (aβ,k /aβ,⊥ ). The angle β varied between 20◦ to 27◦ for γ = 0◦ while angle β got smaller
with γ = 20◦ . Average value of angle β was found to be ≈ 22◦ ±4◦ [136].

Table 4.4: Orientation of β−Strand in Lipid Membrane in Terms of β−Angle Under Various
Buffer Conditions
xchol

xchol

Dry
β (◦ )

Rβ

D2 O Vapor
β (◦ )

Rβ

γ = 0◦

γ = 20◦

D2 O Buffer
β (◦ )

Rβ

γ = 0◦

γ = 20◦

γ = 0◦

γ = 20◦

0.00

1.464

27.2

25.3

0.00

1.120

21.2

17.2

1.233

22.1

18.5

0.05

1.165

20.1

15.6

0.05

1.010

14.6

4.6

1.066

16.9

10.3

0.10

1.328

24.5

21.8

0.10

1.163

20.2

15.7

1.160

20.1

15.6

0.20

1.303

23.9

20.9

0.20

1.577

29.3

28.0

1.243

22.4

18.9

0.40

1.247

22.5

19.1

0.40

1.194

21.1

17.0

0.890

7.1

*

The quality of lipid multilayers was tested based on the order parameter (S) of the acyl chain.
Moreover, CH2 vibrational frequencies in the methylene stretching region were also analyzed.
Zero value of order parameter would mean no preferential direction. Similarly, if the vibrational
wave number gets shifted by (4 − 5) cm−1 , this would also indicate some lipid phase transition.
When there was no cholesterol, the membrane was ordered as indicated by the order parameter
value of 0.5 to 0.7. Tatulian et al. reported an order parameter SL value of 0.3 to 0.6 for PC/PG
multilayers [137]. Similarly, the order parameter for extruded lipid vesicles composed of PC was
reported to vary from 0.24 to 0.80 [138]. Based on these lipid order parameter data, we found that
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lipid vesicles in buffer are very similar in property to that formed in supported multilayer followed
by hydration using D2 O buffer. The calculated ordered parameter value and CH2 vibrational shift
indicates a complex non−monotonous role of cholesterol i.e. ordered membrane at low cholesterol
value and disordered membrane at high cholesterol value [136].

4.2.5

Structure of the Pore

Using all above experimental constraints and standard geometry of β−barrels, the structure of
the pore was identified. A typical sketch of a β−stranded barrel is shown in Fig. 4.16. The
alignment of side chains of consecutive amino acids in the given β−strand must be in and out of
the barrel alternatively. The H−bonding should be perpendicular to the side chains and strand axes
[139, 140, 141, 142]. We considered the following cases:

1. Structure I: S26 , K28 , A30 , I32 , L34 are inside the barrel and G25 , N27 , G29 , I31 , G33 , M35 are
outside.
2. Structure II: S26 , K28 , A30 , I32 , L34 are outside the barrel and G25 , N27 , G29 , I31 , G33 , M35 are
inside.

Using the van der Waals volumes of amino acids [144] determined earlier, for structures I and II, the
3

3

volumes required was calculated to be 3138 Å and 2928 Å respectively for these two topologies
to accommodate the inward oriented side chains of six strands. Similarly, for an 8−stranded barrel,
3

3

the required volumes were calculated to be 4184 Å and 3904 Å for respective configurations. The
radius of barrel is written as [139]
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Figure 4.16: Sketch of a β−stranded barrel. The strands are oriented at an angle β with respect to
the central axis of barrel and barrel axis is at angle γ with membrane normal.

R=

d
,
2sin(π/z)cosβ

(4.1)

where z is the number of strands in the barrel, and β is the strand angle relative to the cylindrical
axis and d is the interstrand distance as shown in Fig. 4.17 (b).
We can use the following formula to find the internal volume of β−barrel:

V = πR2 hb ,
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(4.2)

Figure 4.17: (a) Cartoon structure of Aβ25−35 with hydrogen bonding between S26 and K28 as
shown by the dotted line. Color code is as follow: carbon in gray, nitrogen in blue, oxygen in red,
and sulfur in yellow. Hydrogen atoms are not shown for clarity. (b) Model of 6−stranded β−barrel
of the peptide in unwrapped form (inside barrel view). (c) Cartoon for a 6−stranded β−barrel (d)
Cartoon for a 8−stranded β−barrel of Aβ25−35 (ribbon format), using residues (90 − 100) of αB
crystallin (reference: PDB code 3sgn). This forms “cylindrin” structure consisting of 6−stranded
β−barrel [143]. (e) Proposed pore stabilizing H−bonding between S26 and K28 of one strand with
K28 and S26 of adjacent strand in β−barrel.

where hb is the barrel height given by

hb = macosβ,
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(4.3)

and m being number of amino acids in the strand.

Figure 4.18: Side view (a) and top view (along the pore axis) (b) of αB crystallin residues (90 −
100) (reference: PDB code 3sgn).

For standard barrels, d = 4.7 Å, and inter residue distance is a = 3.48 Å. For Aβ25−35 , m = 11
3

and β = 22◦ , for 6−and 8−stranded barrels, we obtained R6 = 5.09 Å, V6 = 2890 Å , R8 =
3

6.65 Å, and V8 = 4930 Å . Both structures are possible as shown in Fig. 4.17 (c, d). Moreover,
6−stranded β−barrel are tightly packed and 8−stranded structures with internal cavity of 750 Å

3

3

to 1000 Å will have a radius of 2.6 Å to 3.0 Å. The free volume might be randomly distributed
without a fixed passageway. Hence, the Ca2+ transporting pores/channels are the supra−molecular
structures composed of five to eight 6−stranded barrels. On the other hand, single barrel−like
8−stranded pores are possible, but they may not be able to conduct ions effectively. Here are the
other possibilities:
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Figure 4.19: Top view (along the pore axis) of the final membrane pore (radius of central cavity
about 6.5 Å) formed by Aβ25−35 as hexamer of 6−stranded barrel constructed from αB crystallin
(90 − 100) (reference: PDB code 3sgn), replacing the side chains by Aβ25−35 side chains. Each
barrel is turned about its cylindrical axes by 60◦ relative to its neighbors.

Using R6 = 5.09 Å, a = 2.0 Å, (thickness of side chains), a hexamer of 6−stranded barrel would
provide a pore of radius 6 Å to 7 Å, as shown in Fig. 4.19. The structure was sketched using
αB crystallin (90 − 100) (reference: PDB code 3sgn), replacing the side chains by Aβ25−35 side
chains. It forms 6−stranded β−barrel structure as shown in Fig. 4.18. The first configuration may
involve hydrogen bonding interaction between N−N and some hydrophobic interactions between
I−I. Similarly, the second topology will be accompanied by K−S hydrogen bonding between two
inter−strands and I−L hydrophobic interactions. The interplay of these interactions will stabilize
the supramolecular pore. Because of interstrand staggering, the terminal carbonyl oxygens are not
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involved in hydrogen bonding that helps the pores acquire cation selectivity. The ions are most
likely in hydrated forms during the transport as the energy required for Ca2+ dehydration is greater
than 41.84 kJ M−1 .

4.3

Detection of Early Stage Aggregation of Aβ1−42 Using FRET

Although there have been a lot of research work in the field of protein fluorescence, not much work
has been done in the field of phenylalanine to tyrosine resonance energy transfer even 30 year after
the phenomena was observed in a histonelike protein from Thermoplasma acidophilum [145]. The
problem was likely in detecting the very small intensity of phenylalanine emission. The aim of this
work is to monitor the entire process of aggregation including oligomer formation and fibrillogenesis including identification of the segments of Aβ that initiate such processes using intrinsic FRET.
Amyloid fibril formation by proteins is usually studied by fluorescence techniques, using exogenous fluorophores such as thioflavin T (ThT). The presence of such agents in the protein sample
has two potential pitfalls: (a) the probe may affect fiber formation by intercalating in the fibrillary
structure, and (b) such probes detect only the later stages of aggregation, i.e., fibrillogenesis, and
are insensitive to formation of soluble oligomers, the most cytotoxic species. Along with FRET
experiments, ThT fluorescence was measured in parallel, which indicated temporal dissection of
oligomerization, the onset and progression of fibrillogenesis. Thus, the entire process of peptide
aggregation, including oligomer and fibril formation, could be monitored. CD measurements were
conducted on same samples, elucidating structural changes in the peptides during aggregation.
Thus, F−to−Y FRET, combined with ThT fluorescence and structural techniques, illuminates the
full range of molecular events during oligomerization and fibrillization of amyloid peptides and
provides valuable insight in the mechanism of their cytotoxic effects.
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4.3.1

FRET For Soluble Oligomer Detection

I this section, I will describe the results obtained from Forster Resonance Energy Transfer (FRET)
using different segments of Aβ1−42 . We purchased different segments of Aβ1−42 depending on
the position of phenylalanine (F) and tyrosine (Y) and also based on types of residues present as
shown in Table 4.20. The fluorescent amino acid F is colored blue and tyrosine Y is colored red.
The purpose of this work is to detect oligomers of Aβ1−42 or figure out the early stage aggregation
pattern and its origin how it starts out without using any external probe. For this, we first optimized
the excitation wavelengths for both phenylalanine and tyrosine to make sure excitation of phenylalanine doesn’t excite tyrosine. The phenylalanine can be excited at two excitation wavelengths
≈ 220 nm and 265 nm. The optimized wavelength were 220 nm for phenylalanine and 278 nm for
tyrosine. Any residual intrinsic tyrosine emission was subtracted during data processing.
The peptides were dissolved in hexafluoroisopropanol (HFIP), dried by desiccation, and suspended
in aqueous buffer of 25 mM NaCl, 20 µM thioflavin−T (ThT), and 25 mM Na,K−phosphate buffer
(pH 7.2). We have used several possible combinations of different sections of peptide for this
study. As the phenylalanine (F) and tyrosine (Y) are in peptide segments Aβ1−10 , Aβ6−15 , Aβ11−20 ,
Aβ16−25 , Aβ11−28 and Aβ28−11 , we focused out work mainly in that direction. The FRET can occur
when fluorescent residues called donor and acceptors are within a certain distance called Forster
distance. If the residues are that close, then excitation of phenylalanine (F) gives an emission spectra which overlaps with the absorption spectra of tyrosine (Y). The emission energy then transfers
to tyrosine and excites tyrosine. In this event, there will be decrease in donor fluorescence and
increase in acceptor emission. This will require proper orientation of F and Y and within a given
distance. The several possible combinations are as shown in Fig. 4.21. The blue stretch denotes
phenylalanine segment and red denotes tyrosine segment.
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Figure 4.20: Different segments of peptide Aβ1−42 fragments that have been studied. Phenylalanine (F) and tyrosine (T) residues are highlighted yellow and red, respectively.

Oligomer formation was monitored by measuring fluorescence resonance energy transfer (FRET)
between phenylalanine (F) and tyrosine (Y). As shown in Table 4.20, peptide 1 has both F and Y,
so its aggregation in a certain alignment could produce FRET. Formation of Aβ1−10 /Aβ11−20 or
Aβ6−15 /Aβ16−25 hetero−oligomers in a parallel, in−register alignment would produce FRET as
well. Phenylalanine was excited at a wavelength where tyrosine is not excited, and consecutive
fluorescence spectra were recorded to monitor time−dependent changes in F and Y emissions
around 280 nm and 310 nm, respectively. The optimal excitation wavelength was found to be
220 nm. The spectra of peptides 1 and 3 (100 µM) measured individually were subtracted from the
the spectrum of the the mixture of these two peptides (50 µM each) at same time point, multiplied
by 2 (to make correction for concentration). These difference fluorescence spectra were obtained
for Aβ1−10 /Aβ11−20 and Aβ6−15 /Aβ16−25 peptide systems over 200 h, and F to Y FRET during
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hetero−oligomer formation was manifested by a reduction of F emission intensity around 280 nm
paralleleld with enhancement of Y intensity around 310 nm. The plots of difference F and Y
fluorescence intensities against time reflected the kinetics of aggregation.
Homo−oligomers of Aβ1−10 under certain alignment and Aβ1−10 /Aβ11−20 or Aβ6−15 /Aβ16−25
hetero−oligomers in a parallel, in register alignment can produce FRET. In case of the Aβ1−10 /Aβ11−20
system, strong FRET effect developed between 0 h to 10 h of incubation of the two peptides, which
sustained for around 40 h and diminished by 50 h of incubation. In case of the Aβ6−15 /Aβ16−25
system, FRET appeared upon mixing the two peptides, albeit at a lower intensity, and sustained
for the entire period of incubation. These data imply that peptides 1 and 3 gradually form parallel,
in−register aggregates, which disperse by 50 h time point, where the peptide start forming fibrils,
which evidently have a different structure. Conversely, peptides 2 and 4 form parallel or antiparallel aggregates; these structures cannot be distinguished based on the present data. Also, it is not
clear if the transition from oligomers to fibrils involves structural changes for the latter system.
ThT data show dissection of ThT−oligomers into monomers but no early stage fibers formation.
Using FTIR and FRET for other sections of peptide, we plan to bring early−stage oligomerization
pathways at molecular level.

Figure 4.21: Several possible arrangements of different segments of peptide Aβ1−42 .
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Because F has very weak emission intensity, and Y has much bigger intensity, it may not be easy
to see FRET transfer just by looking into peaks. Hence, to effectively monitor FRET, we used a
spectral subtraction method called “Difference Spectrum” defined as

220
DS = 2Fxy
− (Fx220 + Fy220 )

As we see from the Table 4.20, the most expected FRET pair would be a mixture of peptide 1 and
peptide 3 and also another mixture of peptide 2 and peptide 4. Hence we started with these

Figure 4.22: Structures of peptides Aβ1−10 , Aβ11−20 and their equimolar mixture in HFIP and dry
states (left panels). Right panels show similar structures of peptides Aβ6−15 , Aβ16−25 and their
equimolar mixture in HFIP and dry states respectively using CD.
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mixtures. The structures of these peptides, individually and in equimolar mixture in dry states and
in HFIP are shown in Fig. 4.22. The structures are in helical conformation except for peptide
2, 4 and their mixture where turn structure is dominant. Now, we measured the FRET occurring
between peptides 1 and 3 in their equimolar mixture and that of the mixture of 2 and 4 are as
shown in Fig. 4.23. Similarly, for the structural information of these peptide segments and their
combination, CD measurements were also done at the same time as shown in Fig. 4.24.

Figure 4.23: FRET difference spectra and time dependence of difference F and Y fluorescence
intensities for Aβ1−10 /Aβ11−20 (A,B) and Aβ6−15 /Aβ16−25 (C,D). In panels A and C, the insets
show the hours of incubation in buffer (25 mM NaCl, 20 µM ThT, 25 mM Na,K−phosphate, pH
7.2) at 25 ◦C.
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4.3.2

Secondary Structure Change During Oligomerization Using CD

The peptides’ secondary structural changes during aggregation were studied by circular dichroism
(CD) spectroscopy. CD spectra of peptide 1 show a prominent minimum around 200 nm to 205 nm,
indicating mostly unordered structure. The spectra of peptide 3 adopt a different shape, dominated
by a minimum around 225 nm and a maximum around 200 nm, possibly indicating β−turn structure. The mixture of peptide 1 and 3 produces CD spectra that include the features of the spectra
of individual peptides. The structural features of peptides 2 and 4, and their mixture are different.

Figure 4.24: CD spectra of Aβ1−10 (A), Aβ11−20 (B), equimolar mixture of Aβ1−10 and Aβ11−20
(C), Aβ6−15 (D), Aβ16−25 (E), and the equimolar mixture of Aβ6−15 and Aβ16−25 (F) at various time periods of incubation in aqueous buffer containing 25 mM NaCl, 20 µM ThT, 25 mM
Na,K−phosphate, pH 7.2 at temperature 25 ◦C.
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These peptides tend to stay in unordered conformation during the entire 200 h time period of incubation in aqueous buffer.

4.4

FTIR and ssNMR Analysis of Neurotoxic Peptides Aβ1−42 and pEAβ3−42 in Membrane

In order to monitor the structure of these neurotoxic peptides in lipid membrane, we analyzed FTIR
and ssNMR data in unlabeled and corresponding labeled peptides. We used different peptides
Aβ1−42 and pEAβ3−42 with

13

C,

15

indicated by red color. Similarly,

N−segmentally labeled at

13

C,

15

16

K17 L18 V and

36

V37 G38 G39 V as

N−uniformly labeled Aβ1−42 was also used as shown

below.
Aβ1−42 :
1

1

DAEFRHDSGYEVHHQ16 K17 L18 VFFAEDVGSNKGAIIGLMVGGVVI42 A

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM36 V37 G38 G39 VVI42 A
pEAβ3−42 :
p3 EFRHDSGYEVHHQ16 K17 L18 VFFAEDVGSNKGAIIGLMVGGVVI42 A
p3 EFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM36 V37 G38 G39 VVI42 A
Aβ1−42 :
1

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVI42 A

4.4.1

FTIR Shows Different Aggregation Pathways of Aβ1−42 and pEAβ3−42

The sample preparation steps for membrane−peptide reconstitution were as described in materials
and methods section. The peptide was reconstituted in lipid membrane in 10 mM Na,K−phosphate
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Figure 4.25: FTIR spectra of Aβ1−42 in lipid membrane and corresponding time dependence of the
values of Iβ /Iα in 10 mM Na,K−phosphate with pD 7.2, in peptide to lipid ratio of P : L = 1 : 50.
Lipid composition is 60 % POPC, 30 % POPG and 10 % cholesterol.

buffer with pD 7.2, in peptide to lipid ratio of 1 : 50. Lipid composition was 60 % POPC, 30 %
POPG and 10 % cholesterol. FTIR analysis revealed that Aβ1−42 and pEAβ3−42 in membrane stabilized in β−sheet conformation through different aggregation pathways. The Aβ1−42 and pEAβ3−42
peptides in lipid membrane followed distinct conformational pathways. Aβ1−42 initially assumed
partial α−helix (1655 cm−1 ) and β−sheet (1625 cm−1 ) structures in lipid environment. The helix component gradually decreased while the beta sheet components increased over time. After
about 7 h, the structure stabilized in mostly two components: intermolecular β−sheets at about
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1625 cm−1 and γ−turns or unordered structure at about 1687 cm−1 as shown in Fig. 4.25. This
agrees well with the NMR data which showed unordered structures in the region

16

K17 L18 V and

intermolecular β−sheets in the region 36 V37 G38 G39 V. The ratio of β−sheet to α−helix increased
gradually up to 7 h to 8 h and then saturated afterwards. The values of Iβ /Iα are summarized in
Appendix Table C.1.

Figure 4.26: FTIR spectra of pEAβ3−42 in lipid membrane and corresponding time dependence of
the values of Iβ /Iα in 10 mM Na,K−phosphate with pD 7.2, in peptide to lipid ratio of P : L =
1 : 50. Lipid composition is 60 % POPC, 30 % POPG and 10 % cholesterol.

The pEAβ3−42 peptide on the other hand shows unordered structure for the first few hours and
then it acquires two major components; intermolecular β−sheets (1625 cm−1 ) and β/γ−turns or
unordered structures (1675 cm−1 ) with small α−helix component (1656 cm−1 ) as shown in Fig.
4.26. The ratio Iβ /Iα gradually increased for about 15 h and then dropped to reach a plateau. The
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structure then assumed a stable conformation with turn structures (1684 cm−1 ) and intermolecular
β−sheets (1625 cm−1 ). The values of Iβ /Iα are summarized in Table C.2 in Appendix.

4.4.2

Solid State NMR Data Shows Coexisting Ordered (β−Sheet) and Disordered (Turns and
Loops) Regions in Both Peptides Aβ1−42 and pEAβ3−42 in Lipid Membrane.

For the ssNMR characterization of peptides Aβ1−42 and pEAβ3−42 in lipid membrane, previously
described peptide reconstitution methods (Materials and Methods) were used. The peptide reconstitution was done in peptide to lipid ratio of P : L = 1 : 25 in 10 mM Na,K−phosphate buffer

Figure 4.27: 1D CP 13 C−NMR spectra of (a) pure lipid sample with 60 % POPC, 30 % POPG and
10 % cholesterol (b) pure peptide Aβ1−42 with 13 C, 15 N−segmentally labeled at 16 K17 L18 V.

with pD 7.2. Lipid membrane composition was 60 % POPC, 30 % POPG and 10 % cholesterol.
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As a baseline characterization, we first acquired cross polarization (CP) spectra of pure lipid and
pure peptide samples by themselves as shown in Fig. 4.27. Typical sharp and strong resonances
were observed with pure lipid sample in the CP spectrum, indicating a high uniformity in our lipid
preparation. In contrast, both pure Aβ1−42 and pEAβ3−42 with
16

13

C,

15

N−segmentally labeled at

K17 L18 V exhibited broad NMR linewidth (3 ppm to 4 ppm) as shown in Fig. 4.27 indicating

highly inhomogeneous and polymorphic conformation. Similar broad resonances were observed
with Aβ1−42 and pEAβ3−42 peptides 13 C, 15 N−segmentally labeled at 36 V37 G38 G39 V. This highly
heterogeneous conformation of Aβ agrees with Wei Qiang et al. [146].

Figure 4.28: 1D CP 13 C−NMR spectra of peptide (c) Aβ1−42 and (d) pEAβ3−42 reconstituted in
lipid membrane. Peptides are 13 C, 15 N−segmentally labeled at 16 K17 L18 V.

In contrast, when reconstituted in lipid membrane, little peptide signals were observed in 1D CP
13

C−NMR spectra for both Aβ1−42 and pEAβ3−42 −segmentally labeled at residues 16 K17 L18 V as
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shown in Fig. 4.28. It suggests that

16

K17 L18 V region in both peptide samples reconstituted in

lipids is disordered, likely in looped region. This agrees with the existing models by Y. Ishii and
R. Tycko [48, 147].

Figure 4.29: 1D 13 C−NMR spectra of the peptide Aβ1−42 with 13 C, 15 N−segmentally labeled at
36

V37 G38 G39 V (e) CP and (f ) direct π/2 pulse (Onepul) in lipid membrane.

Meanwhile, we observed the downshift of Co and Cα peaks for both peptides 13 C, 15 N−segmentally
labeled at 36 V37 G38 G39 V in their 1D CP 13 C−NMR spectra (which selectively observes rigid signals) and direct π/2 pulse (which can show both rigid and dynamic segments) acquisition spectra
as shown in Fig. 4.29 and Fig. 4.30 respectively. This represents β−sheet conformation in that
region. In addition, the linewidth reduced to 1 ppm or less. It suggests that this region assumes
uniform conformation after reconstitution in lipid membrane. We also observed the membrane
conformational uniformity preserved before and after peptide reconstitution as shown by the simi77

lar line width of lipid components before and after lipid−peptide reconstitution.
Figures 4.29 and 4.30 represent how CP excites selectively only rigid segments and the direct π/2
pulse excites all rigid and dynamic segments. The missing lipid components in 1D CP 13 C−NMR
spectra compared to that in direct π/2 pulse (Onepul) acquisition spectra shows that some lipid
segments, specifically glycerol region (around 60 ppm to 67 ppm) becomes flexible after peptide
reconstitution. This may suggest some preferential interaction of peptide in that region. The
chemical shift values and line widths are summarized in Tables C.3 and C.4 in the Appendix.

Figure 4.30: 1D 13 C−NMR spectra of the peptide pEAβ3−42 with 13 C, 15 N−segmentally labeled
at 36 V37 G38 G39 V (g) CP and (h) direct π/2 pulse (Onepul) in lipid membrane.

After these initial characterization, we performed 2D

13

C−13 C DARR spectrum of the peptide

pEAβ3−42 13 C, 15 N−segmentally labeled at 36 V37 G38 G39 V recorded at 600 MHz resonance with
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Figure 4.31: 2D 13 C−13 C DARR spectrum of the peptide pEAβ3−42 13 C, 15 N−segmentally labeled
at 36 V37 G38 G39 V recorded at 600 MHz resonance with 100 ms mixing time in lipid membrane.

Figure 4.32: Chemical shift of Co , Cα , and Cβ of different residues with respect to random coil
Cr in 2D
36

13

C−13 C DARR spectrum of the peptide pEAβ3−42

13

C,

15

N−segmentally labeled at

V37 G38 G39 V recorded at 600 MHz resonance with mixing time 100 ms in lipid membrane.
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100 ms mixing time in lipid membrane as shown in Fig. 4.31. Based on the chemical shift values of
Co , Cα , and Cβ with respect to the random coil Cr , we again confirmed the down−shift of Co and
Cα and up−shift of Cβ as shown in Fig. 4.32. This indicates 36 V37 G38 G39 V region of pEAβ3−42
assumes β−sheet conformation. The shift were calculated based on the random coil 13 C chemical
shift values summarized in Table C.6 in the Appendix.

Figure 4.33: 2D 13 C−13 C DARR spectrum of 13 C, 15 N−uniformly labeled peptide Aβ1−42 reconstituted in lipid membrane recorded at 600 MHz resonance with 100 ms mixing time.

After these NMR measurements, we aimed at determining the structure of the entire segments of
Aβ1−42 and pEAβ3−42 in lipid environment. The synthesis of pEAβ3−42 was little bit challenging
and time consuming so we decided to start with full length Aβ1−42 . For this purpose, we purchased
13

C, 15 N−uniformly labeled recombinant peptide Aβ1−42 . In order to yield better spectra and sam-

ple quality, we used organic phase mixing reconstitution method by lyophilisation in cyclohexane.
80

This method provided optimal sample packing with almost identical final sample condition.

Figure 4.34: 2D 13 C−13 C DARR spectrum of 13 C, 15 N−uniformly labeled peptide Aβ1−42 reconstituted in lipid membrane recorded at 800 MHz resonance with 25 ms mixing time.

The 2D 13 C−13 C DARR spectrum of 13 C,15 N−uniformly labeled Aβ1−42 was recorded at 600 MHz
resonance with mixing time 100 ms in lipid membrane in the peptide to lipid molar ratio of 1 : 25
as shown in Fig. 4.33. The sample quality and spectral resolution was found very good with
linewidth of 1 ppm or less. DARR spectra were also recorded at 800 MHz resonance with 25 ms
and 50 ms mixing to probe intra−residue contacts as shown in Figures 4.34 and 4.35 respectively.
The higher mixing time of 50 ms did not produce any additional features other than some longer
side chain contacts like LCβ −Cδ , ICα −Cδ , ICβ −Cδ , ICγ −Cδ as shown in Fig. 4.35.
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Figure 4.35: 2D 13 C−13 C DARR spectrum of 13 C, 15 N−uniformly labeled Aβ1−42 reconstituted in
lipid membrane recorded at 800 MHz resonance with 50 ms mixing time.

Figure 4.36: 2D NCA spectra of

13

C,15 N−uniformly labeled Aβ1−42 recorded at 600 MHz reso-

nance in lipid membrane.
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Using 1D and 2D 13 C−13 C DARR spectrum of segmentally labeled and fully labeled peptide, we
were able to make residue type assignments of some of the residues. We also used 2D−NCA and
2D−NCO to identify some additional residues as shown in Fig. 4.36 and Fig. 4.37.

Figure 4.37: 2D NCO spectra of

13

C,15 N−uniformly labeled Aβ1−42 recorded at 600 MHz reso-

nance in lipid membrane.

However, to find tertiary structure and dynamics, sequential assignments will be needed. For this,
we need 3D NCACX and 3D NCOCX. Some of the chemical shift values of identified residues
are shown in Table C.5 in Appendix. The complete sequential assignment of these residues is in
progress. These chemical shift information is used to find the secondary and tertiary structure of the
peptide in lipid membrane. TALOS−N [148] can be used to predict the backbone and side−chain
torsion angle restraints. Using these data together with sequential assignments, the detail structural
of these neurotoxic peptides in lipid membrane will be revealed.
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CHAPTER 5: CONCLUSION

In this chapter, I will summarize the important findings documented in this dissertation and future
outlook. First, the elusive nature of membrane binding mechanism of Aβ25−35 was qualitatively established using experimental procedures. The role of electrostatics in these binding processes were
illustrated using microelectrophoresis experiments. Moreover, the membrane-active structures of
these toxic species were documented precisely. The molecular assembly mechanism, oligomeric
state of these species in active state, i.e. membrane disrupting and pore forming conformation were
also analyzed.
We also shed light on the complex role of cholesterol in Aβ25−35 binding to membrane. To be
precise, key parameters governing the effect of cholesterol such as experimental rate constant, rate
constant of pore formation, peptide−peptide affinity constant, and the number of oligomeric units
in the pore complex were also established along with complete qualitative pathway of structural
transitions in these processes. We also monitored experimentally underlying changes in the lipid
structure and phase during interaction with the peptide with various cholesterol composition. Our
data proved that cholesterol has a dual role during these binding events. It preferentially interacts
with peptide at low concentration, makes lipid more condensed at intermediate concentration and
at very high concentration it makes membrane disordered. Moreover, using experimental data,
we established the structure of the pore as hexamers of hexamers of diameter 13 Å in β−barrel
conformation. These findings will help clear very divergent existing membrane-pore models which
is a key step towards therapeutic anti−Alzheimer’s drug design.
The second part of this work helped to understand the early stage aggregation pathways of Aβ1−42 .
The use of exogenous fluorophores can affect the fiber formation and they are insensitive to formation of soluble oligomers which are the most cytotoxic species. Hence, we used intrinsic FRET
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to qualitatively indicate the temporal dissection of oligomerization, the onset and progression of
fibrilogenesis. This allowed us to monitor the entire process of aggregation. This is another important work because exact knowledge of temporal points on the initiation of oligomer formation
and fibrillogenesis is a key to drug development that can hinder the oligomerization pathway.
Finally, in order to extrapolate and compare the cytotoxic effects of Aβ25−35 to full length peptides
Aβ1−42 and pEAβ3−42 , we performed solid state NMR characterization to find the structure of these
peptides in membrane−active conformation. Because most of the components in Aβ deposits are
full length peptides, it is important to also understand the membranotropic role of these peptides
as well. Our data again points in the direction of formation of fibrillary β−sheets even with these
full length peptides. This work is aimed at providing detail structure of these full length peptides
so that it will contribute to a more precise and targeted therapeutic drug design.
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APPENDIX A: LIST OF ABBREVIATIONS
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The following abbreviations have been used in this dissertation:
AD: Alzheimer’s Disease
APP: Amyloid Precursor Protein
ACH: Amyloid Cascade Hypothesis
Aβ: Amyloid Beta
pEAβ: Pyroglutamylated Amyloid Beta
POPC/PC: 1−Palmitoyl−2−Oleoyl−Phosphatidylcholine
POPG/PG: 1−Palmitoyl−2−Oleoyl−Phosphatidylglycerol
HFIP: Hexafluoroisopropanol
Quin−2: 2 − [(2−Amino−5−methylphenoxy)methyl]−6−methoxy−8−aminoquinoline−N,N,
N’,N’−tetraacetic acid tetrapotassium salt
ThT: Thioflavin T
Phe (F): Phenylalanine
Tyr (Y): Tyrosine
Trp (W): Tryptophan
Cryo−EM: Cryo Electron Microscopy
CD: Circular Dichroism
CPL: Circularly Polarized Light
PEM: Photoelastic Modulator
UV: Ultraviolet
PTM: Photomultiplier Tube
IRE: Internal Reflection Element
DS: Difference Spectrum
FS: Fluorescence Spectroscopy
FTIR: Fourier Transform Infrared Spectroscopy
ATR-FTIR: Attenuated Total Reflection Fourier Transform Infrared Spectroscopy
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SSNMR: Solid State Nuclear Magnetic Resonance
FID: Free Induction Decay
TMS: Tetramethlysaline
FRET: Forster Resonance Energy Transfer
RET: Resonance Energy Transfer
DLS: Dynamic Light Scattering
GP: Generalized Polarization
MAS: Magic Angle Spinning
FWHM: Full Width Half Maximum
DARR: Dipolar Assisted Rotational Resonance
TPPM: Two−Pulse−Phase Modulation
REDOR: Rotational Echo−Double Resonance
CP: Cross Polarization
CaN: Calcineurons
LTP: Long Term Potentiation
LTD: Long Term Depression
MLV: Multilamellar Vesicles
LUV: Large Unilamellar Vesicles
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APPENDIX B: SUPPLEMENTARY DATA OF MEMBRANE PORE
FORMATION
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Table B.1: Concentrations of Membrane Bound Peptide [Pb ] (µM) at Various Aggregation Numbers: z = 1, z = 4 and z = 8
NaCl (mM)

[P ] (µM)

Frel

kexp (s−1 )

[Pb ] (z = 1)

[Pb ] (z = 4)

[Pb ] (z = 8)

10

20

0.1662

5.18 × 10−2

2.86

0.766

0.400

10

40

0.5094

2.69 × 10−2

3.27

0.834

0.423

10

66.7

0.6388

2.30 × 10−2

3.50

0.875

0.439

30

20

0.1691

1.44 × 10−2

1.88

0.515

0.276

30

40

0.3564

1.85 × 10−2

2.16

0.563

0.292

30

66.7

0.5263

2.28 × 10−2

2.30

0.589

0.301

50

20

0.1249

4.33 × 10−2

2.01

0.523

0.269

50

40

0.2779

2.50 × 10−2

2.41

0.600

0.299

50

66.7

0.4128

3.17 × 10−2

2.64

0.648

0.319

75

20

0.1123

2.04 × 10−2

1.76

0.493

0.271

75

40

0.2137

3.66 × 10−2

2.21

0.577

0.303

75

66.7

0.3530

3.06 × 10−2

2.49

0.630

0.323

150

20

0.0898

1.19 × 10−2

1.75

0.315

0.107

150

40

0.1244

1.63 × 10−2

2.22

0.416

0.145

150

66.7

0.1955

1.26 × 10−2

2.50

0.489

0.174

180

66.7

0.1089

3.00 × 10−2

2.47

0.459

0.147

225

66.7

0.1758

6.18 × 10−2

2.41

0.381

0.088

300

66.7

0.163

4.41 × 10−2

2.38

0.337

0.059
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Table B.2: Second Order Rate Constant of Pore Formation ka (M−1 s−1 ) at Various Aggregation
Numbers: z = 1, z = 4 and z = 8
NaCl (mM)

[P ] (µM)

Frel

kexp (s−1 )

ka (z = 1)

ka (z = 4)

ka (z = 8)

10

20

0.1662

5.18 × 10−2

5.907 × 103

2.206 × 104

4.224 × 104

10

40

0.5094

2.69 × 10−2

5.925 × 103

2.323 × 104

4.581 × 104

10

66.7

0.6388

2.30 × 10−2

1.255 × 104

5.020 × 104

1.001 × 105

30

20

0.1691

1.44 × 10−2

1.693 × 104

6.178 × 104

1.153 × 105

30

40

0.3564

1.85 × 10−2

2.942 × 104

1.129 × 105

2.176 × 105

30

66.7

0.5263

2.28 × 10−2

2.923 × 104

1.142 × 105

2.234 × 105

50

20

0.1249

4.33 × 10−2

6.527 × 104

2.508 × 104

4.877 × 104

50

40

0.2779

2.50 × 10−2

1.393 × 104

5.596 × 104

1.123 × 105

50

66.7

0.4128

3.17 × 10−2

2.452 × 104

9.990 × 104

2.026 × 105

75

20

0.1123

2.04 × 10−2

2.631 × 104

9.391 × 104

1.708 × 105

75

40

0.2137

3.66 × 10−2

4.563 × 104

1.748 × 105

3.328 × 105

75

66.7

0.3530

3.06 × 10−2

3.297 × 104

1.303 × 105

2.542 × 105

150

20

0.0898

1.19 × 10−2

1.776 × 104

9.871 × 104

2.906 × 105

150

40

0.1244

1.63 × 10−2

1.313 × 104

7.010 × 104

2.011 × 105

150

66.7

0.1955

1.26 × 10−2

1.296 × 104

6.626 × 104

1.862 × 105

180

66.7

0.1089

3.00 × 10−2

2.561 × 103

1.381 × 104

4.304 × 104

225

66.7

0.1758

6.18 × 10−2

4.103 × 102

2.595 × 103

1.121 × 104

300

66.7

0.163

4.41 × 10−2

2.385 × 102

1.684 × 103

9.538 × 103
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Table B.3: Peptide−Peptide Affinity Constant KP (M−1 ) at Various Aggregation Numbers: z = 1,
z = 4 and z = 8
NaCl (mM)

[P ] (µM)

Frel

kexp (s−1 )

KP (z = 1)

KP (z = 4)

KP (z = 8)

10

20

0.1662

5.18 × 10−2

1.141 × 105

4.258 × 105

8.155 × 105

10

40

0.5094

2.69 × 10−2

2.199 × 105

8.623 × 105

1.700 × 106

10

66.7

0.6388

2.30 × 10−2

5.458 × 105

2.183 × 106

4.351 × 106

30

20

0.1691

1.44 × 10−2

1.489 × 106

5.437 × 106

1.014 × 107

30

40

0.3564

1.85 × 10−2

1.593 × 106

6.114 × 106

1.179 × 107

30

66.7

0.5263

2.28 × 10−2

1.282 × 106

5.004 × 106

9.792 × 106

50

20

0.1249

4.33 × 10−2

1.508 × 105

5.797 × 105

1.127 × 106

50

40

0.2779

2.50 × 10−2

5.577 × 105

2.240 × 106

4.495 × 106

50

66.7

0.4128

3.17 × 10−2

7.739 × 105

3.153 × 106

6.406 × 106

75

20

0.1123

2.04 × 10−2

1.287 × 106

4.595 × 106

8.359 × 106

75

40

0.2137

3.66 × 10−2

1.247 × 106

4.777 × 106

9.096 × 106

75

66.7

0.3530

3.06 × 10−2

1.070 × 106

4.255 × 106

8.300 × 106

150

20

0.0898

1.19 × 10−2

1.491 × 106

8.285 × 106

2.439 × 107

150

40

0.1244

1.63 × 10−2

8.041 × 105

4.291 × 106

1.231 × 107

150

66.7

0.1955

1.26 × 10−2

1.028 × 106

5.256 × 106

1.477 × 107

180

66.7

0.1089

3.00 × 10−2

8.533 × 105

4.603 × 106

1.434 × 107

225

66.7

0.1758

6.18 × 10−2

6.642 × 105

4.201 × 106

1.185 × 107

300

66.7

0.163

4.41 × 10−2

5.407 × 105

3.819 × 106

2.163 × 107
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Table B.4: Oligomeric State (Number of Peptide Oligomers) of the Pore n
NaCl (mM)

[P ] (µM)

Frel

kexp (s−1 )

n (No. of Oligomers)

10

20

0.1662

5.18 × 10−2

3.4

10

40

0.5094

2.69 × 10−2

2.6

10

66.7

0.6388

2.30 × 10−2

3.1

30

20

0.1691

1.44 × 10−2

8.2

30

40

0.3564

1.85 × 10−2

6.3

30

66.7

0.5263

2.28 × 10−2

4.4

50

20

0.1249

4.33 × 10−2

3.6

50

40

0.2779

2.50 × 10−2

4.8

50

66.7

0.4128

3.17 × 10−2

4.6

75

20

0.1123

2.04 × 10−2

8.6

75

40

0.2137

3.66 × 10−2

7.4

75

66.7

0.3530

3.06 × 10−2

5.7

150

20

0.0898

1.19 × 10−2

9.8

150

40

0.1244

1.63 × 10−2

7.4

150

66.7

0.1955

1.26 × 10−2

7.5

180

66.7

0.1089

3.00 × 10−2

8.4

225

66.7

0.1758

6.18 × 10−2

6.3

300

66.7

0.163

4.41 × 10−2

5.9
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Table B.5: Concentrations of Membrane Bound Peptide [Pb ] (µM) at Various Aggregation Numbers: z = 1, z = 4 and z = 8 for Zwitterionic Lipid Vesicles Composed of 90 % POPG and 10 %
Cholesterol in Buffer Containing 75 mM NaCl, 30 mM Myo−Inositol, 6 mM CaCl2 , and 20 mM
Tris−HCl (pH 7.2)
[P ] (µM)

Frel

kexp (s−1 )

[Pb ] (z = 1)

[Pb ] (z = 4)

[Pb ] (z = 8)

20

0.01697

1.058 × 10−2

1.05

0.0573

0.00301

40

0.04197

1.314 × 10−2

1.52

0.0980

0.00582

66.7

0.1018

1.051 × 10−2

1.88

0.139

0.00929

Table B.6: Second Order Rate Constant of Pore Formation ka (M−1 s−1 ) at Various Aggregation
Numbers: z = 1, z = 4 and z = 8 for Zwitterionic Lipid Vesicles Composed of 90 % POPG
and 10 % Cholesterol in Buffer Containing 75 mM NaCl, 30 mM Myo−Inositol, 6 mM CaCl2 , and
20 mM Tris−HCl (pH 7.2)
[P ] (µM)

Frel

kexp (s−1 )

ka (z = 1)

ka (z = 4)

ka (z = 8)

20

0.01697

1.058 × 10−2

7.575 × 103

1.388 × 105

2.642 × 106

40

0.04197

1.314 × 10−2

7.684 × 103

1.192 × 105

2.007 × 106

66.7

0.1018

1.051 × 10−2

7.082 × 103

9.580 × 104

1.434 × 106
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Table B.7: Peptide−Peptide Affinity Constant Kp (M−1 ) at Various Aggregation Numbers: z = 1,
z = 4 and z = 8 for Zwitterionic Lipid Vesicles Composed of 90 % POPG and 10 % Cholesterol
in Buffer (75 mM NaCl, 30 mM Myo−Inositol, 6 mM CaCl2 , and 20 mM Tris−HCl, pH 7.2)
[P ] (µM)

Frel

kexp (s−1 )

Kp (z = 1)

Kp (z = 4)

Kp (z = 8)

20

0.01697

1.058 × 10−2

7.159 × 105

1.312 × 107

2.497 × 108

40

0.04197

1.314 × 10−2

5.863 × 105

9.053 × 106

1.525 × 108

66.7

0.1018

1.051 × 10−2

6.737 × 105

9.114 × 106

1.364 × 108

Table B.8: Oligomeric State of the Pore n at Various Aggregation Numbers: z = 1, z = 4 and
z = 8 for Zwitterionic Lipid Vesicles Composed of 90 % POPG and 10 % Cholesterol in Buffer
Containing 75 mM NaCl, 30 mM Myo−Inositol, 6 mM CaCl2 , and 20 mM Tris−HCl at pH 7.2
[P ] (µM)

Frel

kexp (s−1 )

n

20

0.01697

1.058 × 10−2

8.1

40

0.04197

1.314 × 10−2

7.3

66.7

0.1018

1.051 × 10−2

6.8
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Table C.1: Iβ /Iα Values for Aβ1−42 Reconstituted in Lipid Membrane in Buffer Consisting of
10 mM Na,K−Phosphate with pD 7.2, in Peptide to Lipid Ratio of P : L = 1 : 50. Lipid
Composition is 60 % POPC, 30 % POPG and 10 % Cholesterol
Time (h)

Iβ /Iα

Time (h)

Iβ /Iα

2.93

1.102711

40.91

2.56057

4.93

1.147687

52.68

2.490982

5.41

1.202958

65.25

2.547443

5.66

1.346677

77.66

2.500884

5.90

1.398877

88.85

2.380106

6.18

1.46033

101.11

2.384582

6.41

1.587431

111.31

2.501619

6.98

1.748604

123.25

2.426039

7.45

2.273357

135.70

2.474541

30.95

2.713397
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Table C.2: Iβ /Iα Values for pEAβ3−42 Reconstituted in Lipid Membrane in Buffer Consisting
of 10 mM Na,K−Phosphate with pD 7.2, in Peptide to Lipid Ratio of P : L = 1 : 50. Lipid
Composition is 60 % POPC, 30 % POPG and 10 % Cholesterol
Time (h)

Iβ /Iα

Time (h)

Iβ /Iα

0

0.763505

25.8667

1.77796

3.01667

1.41842

34.9

1.77212

3.31667

1.43812

40.65

1.72761

3.7

1.46271

56.95

1.49936

4.21667

2.02377

62.2667

1.50759

4.9333

2.11994

69.85

1.52298

8

2.7835

81.8667

1.57029

12.55

3.27698

93.3667

1.61269

15.5667

3.43633

105.8

1.66204

20.55

1.78781

118.7

1.72867
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Table C.3:

13

C Chemical Shift and FWHM of Pure Lipid and Aβ1−42 with

13

C Uniformly La-

beled Residues in the Region 16 K17 L18 V. Lipid Composition is 60 % POPC, 30 % POPG, and 10 %
Cholesterol
Sample

Lipid Mixture *

Aβ1−42 (16 K17 L18 V)

13

Region of Interest

C Chemical Shift (ppm)

Line Width (ppm)

Aliphatic: αCH2

34.702

Aliphatic: (ω−2)CH2

32.731

Aliphatic: (CH2 )n

30.809

Aliphatic: βCH2

28.038

Aliphatic: (ω−1)CH2

25.702

Aliphatic: ωCH3

23.327

Triacylglycerol (glyc−1,3)

64.358

0.485

Triacylglycerol (glyc−2)

71.256

0.486

Olefinic CH2

130.335

0.324

C=O

172.759

3.39

Cα

59.138, 52.502

2.42, 3.075

Cβ

40.687, 32.918

4.53, 3.076

Cγ

24.340, 18.999

5.17, 4.53
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1.294

Table C.4:

13

C Chemical Shift and FWHM of Aβ1−42 and pEAβ3−42 with 13 C Uniformly Labeled

Residues in the Region

36

V37 G38 G39 V in Lipid Membrane. Lipid Composition is 60 % POPC,

30 % POPG, and 10 % Cholesterol
Sample

Region of Interest

13

C Chemical Shift (ppm)

Line Width (ppm)

C=O

172.196, 169.444

1.942, 1.943

Aβ1−42 (16 K17 L18 V)

Cα

57.653, 57.310, 43.838

1.832, 1.78

in Lipid

Cβ

−

−

Cγ

19.515

1.459

C=O

171.387, 168.635

1.943, 1.78

pEAβ3−42 (16 K17 L18 V)

Cα

57.111, 43.352

2.49, 1.94

in Lipid

Cβ

33.479

1.96

Cγ

19.073

1.295
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Table C.5:

13

C Chemical Shift and FWHM of Identified Residues of 13 C, 15 N Uniformly Labeled

Aβ1−42 in Lipid Membrane. Lipid Composition is 60 % POPC, 30 % POPG, and 10 % Cholesterol
at Peptide to Lipid Ratio P : L = 1 : 25
Identified Residues

Ile (I)

Ala (A)

Leu (L)

Val (V)

Met (M)

Region of Interest

13

C Chemical Shift Value (ppm)

Cα

59.187 − 60.270

Cβ

39.288 − 41.967

Cγ

16.790 − 18.550

Cδ

13.913 − 14.224

Cα

51.421, 51.300

Cβ

20.344, 22.892

Cγ

33.479

Cα

54.212 − 56.154

Cβ

41.957 − 46.189

Cγ

27.503 − 28.231

Cδ

25.562

Cα

58.823 − 62.220

Cβ

34.419 − 36.188

Cγ

19.073

Cα

54.819, 55.062

Cβ

36.603

Cγ

32.478

101

13

Identified Residues

Region of Interest

Arg (R)

Cγ

27.624

Cδ

46.689

Cα

52.392

Cβ

41.214

Cα

59.915

Cβ

41.093

Cα

58.201

Cβ

63.919

Asn (N)

Tyr (Y)

Ser (S)
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C Chemical Shift Value (ppm)

Table C.6: Random Coil 13 C Chemical Shifts for the 20 Common Amino Acids
Residue

N

Co

Cα

Cβ

Others

Ala (A)

123.8

175.9

50.5

18.1

−

Cys (reduced) C

118.8

173.0

56.4

27.1

−

Asp (D)

120.4

175

52.2

40.9

γCO 179.9

Glu (E)

120.2

174.9

54.2

29.2

γCH2 35.0; δCO 183

Phe (F)

120.3

174.4

55.6

39.1

1C 138.9; 2, 6CH 132.1; 3, 5CH 131.4; 4CH 129.9

Gly (G)

108.8

174.5

44.5

−

−

His (H)

118.2

172.6

53.3

29.0

2CH 136.3; 4CH 120.3; 5C 131.2

Ile (I)

119.9

175.0

58.7

38.7

γCH2 26.9; γCH3 17.1; δCH3 12.7

Lys (K)

120.4

174.8

54.2

32.6

γCH2 24.6; δCH2 29.1; CH2 41.9

Leu (L)

121.8

175.7

53.1

41.7

γCH 27.1; δCH3 25.1, 3.3

Met (M)

119.6

174.6

53.3

32.4

γCH2 32.0; CH3 17.0

Asn (N)

118.7

173.6

51.3

38.7

γCO 177.1

Pro (P)

147.3

171.4

61.5

30.9

γCH2 27.2; δCH2 49.7

Glu (Q)

119.84

174.4

53.7

28.8

γCH2 33.4; δCO 180.5

Arg (R)

120.5

174.5

54.0

30.2

γCH2 26.8; δCH2 43.4; C 159.6

Ser (S)

115.7

173.1

56.4

63.3

−

Thr (T)

113.6

173.2

59.8

69.8

γCH3 21.4

Val (V)

119.2

174.9

59.8

32.6

γCH3 20.9, 20.1

Trp (W)

121.3

174.8

55.7

28.9

2CH 127.3; 3C 111.3; 4CH 122.2; 5CH124.8;
6CH 120.9; 7CH 114.7; 8C 138.8; 9C 129.6

Tyr (Y)

120.3

174.8

55.8

38.3
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1C 130.7; 2, 6CH 133.5; 3, 5CH 118.2; 4C 157.3
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